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Optical medical imaging is a new technology that uses light to improve clinical 
processes such as disease diagnosis and tumour margin delineation. It has the 
potential to produce high-resolution images in real-time, with continuously 
generated images on or in biological tissues at a molecular level. Imaging 
inside the lung can be accomplished via the use of microendoscopy, and this 
has been used to detect and analyse several pulmonary diseases, which 
traditionally have been hard to unequivocally define.  
Several pulmonary diseases have been linked with overactive leukocytes 
within the lung. A class of leukocytes, neutrophils, are used by the body to 
aggressively destroy potential pathogens with an arsenal of proteases 
including human neutrophil elastase (HNE) at its disposal. However, 
overexpression of unregulated HNE has been implicated in a number of 
pulmonary diseases, such as fibrosis, COPD and acute lung injury with 
irreversible damage caused to lung tissue through protein degradation. 
Currently in the clinic, it is difficult to identify and quantify unregulated HNE 
in vivo using traditional methods of diagnosis. Thus, the ability to quantify and 
evaluate numbers of neutrophils and levels of HNE using an in vivo technique 
would be very valuable.  
Within this work, a library of optical probes to selectively detect HNE at a 
molecular level were designed and evaluated. The probes consist of two parts: 
an inhibitor warhead designed to irreversibly bind to HNE, and a fluorophore. 
Two different classes of warheads have been synthesised and conjugated to a 
variety of fluorophores that emit over a range of wavelengths. Having optical 





multiplex imaging so several diseases can be screened simultaneously, as well 
as removing the probes from possible tissue autofluorescence wavelengths. 
The probes were evaluated for their binding efficacy with HNE, toxicity 
against erythrocytes and then, subsequently used to detect and image the 
presence and localisation of HNE within neutrophils. It is envisioned that the 
use of optical probes to detect HNE overexpression will lead to quicker 
diagnoses for patients with debilitating pulmonary diseases.  
 
Dying neutrophil labelled with DAPI (blue), CellTracker green (green) and 









Human neutrophil elastase (HNE) is an enzyme found in neutrophils that is 
used to digest proteins and degrade pathogens. This maintains the body in a 
healthy manner and prevents infections spreading further throughout the 
body. In some diseases, the neutrophil’s response is not switched off, or is 
accidentally switched on, even if no microbe present and so the neutrophil 
starts to digest healthy tissue instead. The damage is irreversible and 
symptomatic of lung diseases such as emphysema, fibrosis and chronic 
obstructive pulmonary disease (COPD). 
In this thesis, several targeting molecules were synthesised to bind to HNE 
and label the enzyme with a fluorescent dye to detect areas with high levels of 
neutrophil activity. The aim of this was to speed up diagnosis of lung diseases, 
as the current gold standard in clinics can be time consuming and 
uncomfortable for the patient. After the synthesis of the optical probes, they 
were tested using purified enzyme and imaged in activated neutrophils to 
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Chapter 1 Introduction 
 
1.1 Optical medical imaging  
 
Medical imaging has been instrumental in disease diagnosis since X-ray 
imaging was first discovered by Röntgen in 1895. The power of imaging being 
demonstrated by the rapid growth of X-ray technologies, and by the start of 
the First World War, most hospitals in the UK had X-ray units within their 
walls.1  Since the 1960’s, several new imaging techniques have come to the 
forefront, such as computed tomography (CT), magnetic resonance imaging 
(MRI), positron emission tomography (PET) and single photon emission 
computed tomography (SPECT) that have radically changed how doctors 
diagnose and monitor patients. X-ray, CT and MRI imaging are mostly 
focussed on determining the topography, whereas PET and SPECT were some 
of the first techniques to incorporate radioactive contrast agents for functional 
imaging.2 PET imaging has been instrumental in improving cancer patient 
survival by elucidation of the location of small tumours before the surgery, as 
well as allowing the clinician a method of monitoring the effectiveness the 
radiotherapy treatment is over time. One of the most widely used imaging 
agents is fluorodeoxyglucose, (18FDG, 1 Figure 1.1), an 18F labelled glucose that 
is used to determine the location of cancerous cells and tumours, due to 
enhanced cancerous cell uptake of 18F-glucose (followed by the 
phosphorylation that leads to ‘trapping’ inside cells), giving hotspots of 







Figure 1.1. Structure of 18F deoxyglucose, one of the most popular PET 
imaging agents. 
 
CT imagery is one of the most popular techniques for hard tissues, due to the 
speed of acquisition and no requirement of a radiotracer. However, it lacks the 
resolution needed for soft tissue unless contrast agents are used.4 Iopromide 
(2, Figure 1.2) is an iodinated contrast agent commonly used to visualise soft 
tissue at higher resolutions, though this requires millimolar concentrations 
which can lead to toxicological issues.2,5 
 
Figure 1.2. The CT contrast agent Iopromide (2, Ultravist), and the MRI 
contrast agent Gd-DTPA, 3.  
 
MRI uses electromagnetic radiation to investigate the anatomy of the patient 
and give more detailed outline of the morphological changes in the structure 
of tissue in both health and disease. The strong magnetic radiation is absorbed 
by hydrogen present in saturated fats and water, and then emitted at a 
radiofrequency that is detected and compiled into an image. Due to the high 
water content in soft tissue ionising radiation is not required, however, 30% of 
MRI procedures in the US use a contrast agent.6 Gd-DTPA (3, Figure 1.2) is an 
FDA approved gadolinium-based contrast agent used in diagnosis of CNS 





is fleeting in healthy tissue, but the enhancement lingers in the presence of 
lymphatic damage and lesions.6,7 MRI gives higher resolution images than 
PET, but is ineffective in emergency medicine due to the length of time 
required for an image. 
Single photon emission computed tomography is the incorporation of 
radiotracers into CT scan. SPECT utilises radiotracers that emit gamma rays, 
unlike PET which uses positron emitting substances.8 The blood flow of the 
patient is monitored by the presence or absence of radiation, for example in 
the treatment of stroke victims, cranial flow can be monitored to detect 
damaged areas of the brain. SPECT offers the advantage of being cheaper and 
more readily available than PET, due to radiotracers used having longer half-
lives (99mTc t1/2 = 6 h, 18F t1/2 = 109 min).9  
There can be pitfalls in using these methodologies, such as cost, limited 
specificity but one of the most significant is the radioactive dose delivered to 
the patient, whether it is through the agent (PET, SPECT) or collecting the 
image itself (X-ray/CT). Additionally, when using PET and SPECT, the 
radiotracer must be synthesised which requires highly specialised equipment 
along with rapid delivery and imaging.10  
The technique of optical medical imaging (OMI) is being rapidly developed 
for diagnostic imaging. With OMI, contrast can be achieved using endogenous 
fluorophores, autofluorescence or specifically developed imaging agents 
containing a fluorophore.11 Using fluorescence offers advantages over other 
imaging modalities, as it requires no radiation and the equipment has the 
potential to be more compact, affordable and mobile.12 Additionally, using 
imaging agents that fluoresce in different spectral ranges allows multiplexing, 
giving the ability to screen multiple targets simultaneously. Optical imaging 
is highly sensitive and can achieve high resolution images, giving in depth 





Optical endomicroscopy uses optical fibres to focus on an accessible area, e.g. 
lungs, gastrointestinal tract, reproductive tract, etc. It can be specifically aimed 
to areas of interest in order to direct biopsy or detect disease.4 However, 
drawbacks for optical endomicroscopy include the limited field of view and 
the need for an optical fibre.4 Reduction of signal can occur through repeated 
excitation of the imaging agent, through photobleaching and the destruction 
of the fluorophore, reducing the ability to monitor the target over a long period 
of time.13  
 
1.1.1 Fluorescence 
OMI can be achieved in vivo using imaging agents and fluorescence. 
Fluorescence is one mechanism that allows the emission of light from a 
compound after the absorption of photons. It can be visualised simply through 
a Jablonski diagram (Figure 1.3).14  
 
 
Figure 1.3. A Jablonski diagram indicating the absorption of photons to excite 
molecules and their subsequent relaxation to generate fluorescence. The 
straight arrows indicate the photon absorption and emission routes, while the 






The molecular ground state is excited by the absorption of a photon, inducing 
its movement to an excited energy level (S1, Figure 1.3) but can reside at any 
number of vibrational energy states, according to Frank-Condon rules. The 
molecule vibrationally relaxes to the closest semi-stable energy level, before 
undergoing internal conversion to move from one excited level to the lowest, 
as Kasha’s rule states that fluorescence will only occur from the lowest excited 
level (S1). Upon reaching it, a photon will be emitted as the electron returns to 
the ground state (fluorescence), or if there is non-radiative relaxation, then 
simply transition to the ground state without emission.  
The molecule can also move to an excited triplet state (T1), in a process known 
as intersystem crossing (ISC, Figure 1.3). ISC is forbidden, as it requires 
changing the spin state of the electron. The electron relaxes from T1, to induce 
phosphorescence (or again, non-radiative relaxation).  
The photons emitted are lower in energy than the photon absorbed therefore 
the emission is at a longer wavelength than the excitation. The difference 
between the excitation and emission maxima is known as the Stokes shift. This 
is indicative of the journey travelled by the photon, as a large Stokes shift 
implies significant energy loss due to excited state transitions. A small Stokes 
shift is suggestive of energy loss simply through changes in vibrational energy 
states. The efficiency of fluorescence can be determined through its so-called 
quantum yield; the percentage of photons emitted divided by the total number 
of photons absorbed. The quantum yield, in addition to the extinction 
coefficient of the fluorophore, can be used to define the ‘brightness’ of the 
fluorophore. 
A fluorophore selected for biological imaging should ideally be chosen to 
avoid intrinsic autofluorescence of physiologically prevalent molecules such 
as haemoglobin, while also avoiding excitation wavelengths capable of 
absorbance by water, etc. (Figure 1.4). This has led to the concept of an ideal in 







Figure 1.4. A graph plotting wavelength versus the extinction coefficients of 
several physiological relevant molecules. Reprinted with permission from 
Chem. Rev. 2010 May 12; 110(5): 2620–2640. Copyright 2009 American 
Chemical Society.15 
 
1.1.2 In vivo optical imaging agents 
When using optical medical imaging the choice of fluorophore can be vital, 
mostly determined by the excitation and emission wavelengths, quantum 
yield, and lifetime. Currently, there are three compounds approved by the 
FDA as imaging agents: the dyes indocyanine green (ICG, 4) and fluorescein 
(5) and 5-aminolevulinic acid.16 ICG (Figure 1.5) is a heptamethine dye that 
has been used in intraoperational angiography for over fifty years, and is 
frequently used to monitor the vascular structure during operations of the 
heart, eye, etc.15,17,18 with far red excitation and emission wavelengths (λEx/Em 
= 785/800 nm) and a high extinction coefficient (ε782 = 194 000 cm-1M-1 in 
EtOH).19 However, its quantum yield is low (Φ = 0.08 in EtOH/H2O, 7:3), but 
this can be overcome by the lack of background fluorescence in the optical 






Figure 1.5. The NIR fluorophore indocyanine green (ICG) (4), (λEx = 785 nm, 
λEm = 800 nm). 
 
Fluorescein, 5, is regularly used in optical angiograms for assessing the 
vascular structure in the eye.21,22 It was originally synthesised by Baeyer in 
1871 through Friedel-Crafts acylation chemistry (Scheme 1.1)23 has large 
quantum yields and extinction coefficients (Φ = 0.95 in aqueous 0.1 M NaOH, 
ε500 92 300 cm-1M-1 in basic EtOH).14,19 It has an excitation wavelength of 494 
nm, with emission at 520 nm, meaning it can be used in parallel with 
fluorophores such as coumarin and heptamethine dyes. The ubiquitous use of 
fluorescein is due to several factors, such as its commercial availability, 
resistance to photobleaching, pH sensitivity, and its high aqueous solubility.  
 
Scheme 1.1. Baeyer’s synthesis of the generation of fluorescein (5). Reaction 
conditions: ZnCl2, Δ. 
 
The fluorophores ICG and fluorescein, whilst still popular in medical imaging, 
lack targeting and cannot be directly attached to a targeting moiety without 
structural modification. One shortcoming of fluorescein based compounds is 





autofluorescence, making it difficult to distinguish background from probe 
fluorescence.24  
5-Aminolevulinic acid hydrochloride (5-ALA, Figure 1.6) is a recently 
approved imaging agent for the detection of glioblastoma tumours during 
surgery.25 Oral administration several hours before surgery allows the small 
molecule to be metabolised (by malignant cells) into the fluorescent metabolite 
Protoporphyrin IX (Figure 1.6). This metabolite has excitation and emission 
maxima of 405 nm and 633 nm and is used to elucidate the outer perimeter of 
the glioblastoma to ensure complete resection of cancerous tissue.25  
 
Figure 1.6. The incorporation of 5-aminolevulinic acid into protoporphyrin IX 
through natural metabolism, to induce a fluorescent signal at 633 nm (when 
excited at 405 nm). 
 
1.2 Neutrophils  
 
There are two branches of immune system, adaptive and innate, and 
neutrophils have been implicated in both.26 The innate immune system is non-
specific and is quick acting, within hours, against pathogens, whereas the 
adaptive is antigen specific and is acquired after interacting with the antigen.27 
There are several types of leukocytes that are constantly monitoring the 
internal environment (Figure 1.7), with neutrophils acting as the first line of 





= 5.4 days) than most other leukocytes (t1/2 of two weeks or more).28 It was 
previously thought to be much less (between 6 and 8 hours) and there is still 
uncertainty around the study.29 They are distinguishable by their polynuclear 
structure and possess numerous membranous sacks of enzymes, or so-called 
azurophil granules, containing various proteases. The main roles of the 
neutrophil include immobilisation of bacteria through cleavage of their 
flagella and subsequent consumption by phagocytosis, as well activating other 
immune cells, such as macrophages, to direct them to the site of infection.30 
Neutrophils regularly apoptose as a method of maintaining the body’s defence 
system against pathogens.31 
 
Figure 1.7. The various blood cells that exist within the human immune 
system. Reprinted with permission from Anatomy & Physiology, Chapter 21, 
OpenStax, copyright 2016.32 
 
The neutrophil contains several degranulative enzymes that aid in 





granules: human neutrophil elastase (HNE), cathepsin G and proteinase 3.33 
There are several methods implemented by the neutrophil to destroy 
pathogens (Figure 1.8).34 The enzymes are stored within the granules and are 
already active and in the first method these remain within the granule. After 
phagocytosis of the bacteria occurs, it can be ‘digested’ within the lysosome 
(A, Figure 1.8). A second route involves activation of neutrophils through 
activation of the formyl peptide receptor 1 (FPR1) by formylated proteins,26 
whereby the azurophilic granule relocates to the cell membrane and is 
‘docked’, presenting the enzymes extracellularly by anchoring them on the 
outer membrane (B, Figure 1.8). This method enables the enzymes to be close 
to the site of inflammation and cover a larger area.  
 
Figure 1.8. Depictions of the methods of pathogen degradation by the 
neutrophil: A) phagocytosis of the pathogen; B) enzymes within the granule 
are ‘docked’ to the outer cell membrane for extracellular attack of the 
pathogen; C) the use of NETs to release the proteases extracellularly in a self-
destructive manner. Adapted by permission from Springer Nature: Nat. Rev. 
Immunol. 2013; 13(3): 159–175, copyright 2013.35 
 
Thirdly, one of the more aggressive methods of bacterial digestion used by the 
neutrophil is the use of neutrophil extracellular traps (NETs, Figure 1.8 Path 





of DNA loops with active proteases attached.36 They act as an extension of the 
neutrophil and surround the bacterium, resulting in increased levels of 
degradation. The enzymes are held in place by ionic bonds formed with the 
chromatin on the DNA loop, preventing them from attacking other 
endogenous proteins nearby.36 These however are a last resort for a neutrophil 
as it induces apoptosis and simultaneously emits signals to other leukocytes 
for them to consume the apoptotic bodies produced.37 Alongside digestive 
enzymes, neutrophils also generate highly reactive oxidative species (such as 
hydrogen peroxide) in the phagolysosome using NADH oxidase to destroy 
pathogens.29,34 
The serine proteases human neutrophil elastase, proteinase 3 and cathepsin G 
all contain the same catalytic triad (His, Asp and Ser) and mechanism of amide 
hydrolysis (Scheme 1.2). The active sites of the enzymes are prone to be 
indiscriminate, to enable their ability to degrade a large range of proteins and 
many of the pathogens.33  
 
1.2.1 Human neutrophil elastase  
Many enzymes in the body are classified as proteases, indeed they encompass 
almost 2% of the human genome.38 The regulation of these proteases plays a 
key role in numerous diseases. HNE is a 29 kDa protease that resides in the 
neutrophil and was originally described by Janoff, who named it after its 
capability to digest elastin.39 It was soon established as having other properties 
such as degrading pathogens. The enzyme is 218 amino acids long (transcribed 
from chromosome 19) and is comprised of a C-terminal α-helix and two β-
barrels, each of which contain six antiparallel β-sheets (Figure 1.9). The barrels 
converge and form the S1 pocket which is hydrophobic due to the presence of 






Figure 1.9. The structure of human neutrophil elastase that has been 
complexed with the GSK inhibitor GW475151. The green feature is an α-helix 
at the C-terminus connected to six antiparallel β-sheets (blue flat arrows) that 
form two β–barrels. The magenta residues in the centre depict the catalytic 
triad.41 
 
Neutrophil elastase is capable of digesting a wide variety of proteins such as 
collagen, fibrin, elastin and fibronectin.42 Examples of pathogen degradation 
include the cleavage of the outer membrane proteins of Gram negative 
bacteria such as E. coli and the degradation of the virulence factors for a wide 
range of enterobacteria preventing them from escaping phagocytosis.43  
HNE is integral to a plethora of signalling pathways for the immune 
responses, both anti and pro-inflammatory.44 The ability to induce a second 
wave of immune response from leukocytes through the release of interleukin-
8 (IL-8) gives a pro-inflammatory response,27 but digesting the cytokines 
tumour necrosis factor alpha (TNF-α) and IL-2 (Interleukin-2) can prevent 





reducing the immune response.45 The most prominent indigenous promoters 
are TNF-α, IL-8, C5a (complement protein 5a) and IL-1β. These are used by the 
immune system to stimulate a response to any form of injury and to induce 
neutrophil aggregation in the vicinity for a swift response. There are other 
HNE promoters that include LPS (lipopolysaccharide) compounds present on 
the outer membrane of Gram-negative bacteria and N-formyl oligopeptides 







Scheme 1.2. Hydrolysis of amide bonds by the catalytic triad histidine, 
aspartic acid and serine within the active site of the enzyme human neutrophil 
elastase. The carbonyl moiety of the peptide undergoes nucleophilic attack 
from the hydroxyl group of the serine residue (I) to generate the tetrahedral 
intermediate (II). The carbonyl is regenerated, breaking the C-N bond to form 
an acyl enzyme intermediate on the serine and liberate an amine (III). The 
water undergoes nucleophilic attack of the ester (IV), hydrolysing the serine 






1.2.2 Human neutrophil elastase in disease 
Due to the methods of enzyme activation within the neutrophil, the pro-
inflammatory response of HNE may be extreme, and this can cause 
irreversible damage to tissue if uncontrolled. Indeed, overexpression of HNE 
induces several chronic inflammatory diseases, such as emphysema, chronic 
obstructive pulmonary disease (COPD), acute lung injury (ALI), fibrosis and 
acute respiratory distress syndrome (ARDS).44,46 Other inflammatory diseases 
with causative HNE levels include psoriasis, where high levels of HNE cleave 
the interleukin-36 receptor antagonist increasing its biological activity, leading 
to degradation of the upper dermal layer of the skin, causing patchy flakes of 
skin and discomfort.47  
Acute lung injury is a mild variety of acute respiratory distress syndrome, and 
is defined as clinical syndromes of respiratory failure after an injury or disease, 
such as sepsis, trauma, acute pancreatitis, etc.48 The injury induces an 
exacerbated inflammatory response that causes proteinase concentrations to 
be unbalanced with excess activated enzymes degrading lung tissue.49 Since 
HNE increases the response by releasing chemokine IL-8, ALI can be 
aggravated over time into a more severe form, ARDS. In a study by Lee, it was 
found that 52% of ARDS patients had high levels of HNE activity in their 
bronchoalveolar lavage (BAL).38 The HNE activity was not reduced by normal 
levels of α1-antiprotease (α1-AP),50 one of the main endogenous protease 
inhibitors.  
Currently, the clinical gold standard for HNE detection in the lung is a BAL; a 
large volume of saline (120 mL) is sprayed into a specific section of the lungs 
and then removed out. Histology is conducted using a variety of staining 
techniques and the fluid cultured to detect the pathogens present.51,52 It can 
take several days for the results of pathogen identification, and most diagnoses 





The difficulty in diagnosing pulmonary diseases associated with high levels of 
HNE leads to vague criteria for a positive diagnosis. Both academia and 
industry have developed small molecule inhibitors for HNE with the aim of 
reducing and managing the symptoms of diseases such as COPD and ALI.53 
This need is obvious by the number of patents published in this sector, and 
has been reviewed succinctly in the last ten years.54–56 The use of optical probes 
as a diagnostic tool for clinicians and as a method to validate drugs, would be 
beneficial to detect certain pulmonary diseases as well to stratify patients, 
preventing further degradation of lung tissue in patients.  
 
1.3 Optical imaging probes 
 
There is a plethora of enzymes present within the body, all up or down 
regulated by the enormous ecosystem contained within. It comes to no 
surprise that the misregulation and overexpression of enzymes has been 
studied for years as a potential mechanism behind several diseases. Because 
of this, there have been a wide range of optical probes generated for the 
investigation and interrogation of isolated proteases, such as caspases,57 and 
other cysteine proteases,58 matrix metalloproteinases, cathepsins,59–61 not to 
mention other enzyme families such as esterases,62 oxidases,63,64 etc.  As HNE 
has been implicated in a wide variety of diseases, there has been interest in 
designing optical probes that are diagnostic tools. In addition, inhibitors have 
been designed as a treatment option for several disease states.56  
One of the first probes to detect HNE was developed by Powers and was a 
chromogenic peptide sequence, MeOSuc-AAPV-pNA (Figure 1.10, 6).65 The 
peptide sequence is cleaved by the enzyme, releasing p-nitroanilide which is 
detected by its absorbance at 405 nm. One of the disadvantages of 6 is the 





be circumvented by using its fluorogenic counterpart, MeOSuc-AAPV-AMC 
(Figure 1.10, 7). It is an umbelliferone based peptide substrate that has a 
quenched fluorescent signal until the umbelliferone is released by cleavage of 
the amide bond. There are still drawbacks of both probes that include their 
non-selectivity for HNE over other proteases, and the presence of the methyl 
succinyl ester that will interact with other enzymes in the body, preventing 
use in vivo. 
 
Figure 1.10. The peptide substrates MeOSuc-AAPV-pNA, 6, a chromogenic 
substrate used to detect the presence of proteases (HNE, kcat/Km = 1.2 × 105 
M-1 s-1), and MeOSuc-AAPV-AMC, 7, its fluorogenic counterpart (HNE, kcat/Km = 
1.1 × 104 M-1 s-1, λEx = 360 nm, λEm = 460 nm). 
 
There are multiple ways to design an optical probe: activity-based, substrate-
based, environmentally sensitive, and always on probes (Figure 1.11). The 
activity-based probes are frequently designed to be a small molecule attached 
to a quenched fluorophore; upon interaction with the enzyme in question, the 





fluorescent signal to be produced.66 If specific enough it can be incredibly 
useful for determining the levels of enzyme activity present in both healthy 




Figure 1.11. Mechanisms of optical probes. A) An activity-based probe, 
whereby the structure of the probe is modified after interacting with the 
enzyme, inducing a fluorescent signal; B) A substrate-based probe, a probe 
with a peptide sequence that can be cleaved to induce fluorescence; C) An 
always-on probe, where the fluorophore has no quenching, but the probe has 
a highly specific binding mechanism towards the target. 
 
Secondly, there are substrate-based probes, mostly peptide sequences that are 
specific to the enzyme of interest (B, Figure 1.11). The peptide might have a 
fluorophore at one or both termini which self-quench or interact in some way. 
Upon cleavage of the substrate by the enzyme, the fluorophores will be 





the fluorophore. Another type of optical probe is ‘always-on’ probes (C, Figure 
1.11). This is when the fluorophore itself has no mechanism of quenching but 
is directly attached to the targeting group of the compound, giving a signal. 
The probe is then only bound by the target, fluorescing and can be imaged in 
its place. This type of probe is beneficial in that it gives more information about 
the quantity of the target and its location whereas the substrate based, and 
activity-based probes mostly give a binary response: fluorescence emission if 
the target is present or no signal. The literature has separated the optical 
probes into these categories for ease of comparison. 
 
1.3.1 Activity-based probes for elastase detection 
The optical probe 8 is an umbelliferone based probe for the detection of HNE, 
(Figure 1.12).67 The pentafluoroethyl acetamide group induces photoinduced-
electron transfer (PeT) quenching, allowing for an ‘off’ state of the probe. 8 was 
further tested after it also showed selectivity towards HNE over other 
enzymes such as chymotrypsin and trypsin. However, they did not do a screen 
of other neutrophil-related proteases.  
There are several parameters that can be used to describe the efficiency of an 
enzyme. Km is the concentration of substrate at which the enzyme is at half 
the maximum velocity and is indicative of how fast the enzyme catalyses the 
reaction. The number of substrate molecules cleaved per unit time can be 
defined as kcat.  
For optical probe 8 they determined the Km to be 20 µM, and the kcat as 22 min-
1 with a limit of detection of 68 ng/mL. Compared to the chromogenic 
substrate MeOSuc-Ala-Ala-Pro-Val-pNA (6, Figure 1.10) it was 7-fold slower 
but they failed to investigate the fluorogenic counterpart MeOSuc-Ala-Ala-





was far cheaper, as is the advantage of small molecular probes over peptide-
based probes.  
 
Figure 1.12. Switch-on optical probes for HNE detection from Yang et al. 8 
(λEx = 490 nm, λEm = 525 nm) and 9 (λEx = 670 nm, λEm = 700 nm), where 
the dashed orange lines indicate the enzyme cleaveage.67,69 
 
The same group published another paper on HNE detection but in the far-red 
region.69 They used a modified Cy7 dye and as before induced self-quenching 
by placing a pentafluoroethyl acetamide on the aniline to generate 9 (Figure 
1.12). However, in a similar manner to their previous paper, they only screen 
non-related enzymes, such as acetylcholinesterase and carboxypeptidase. 
They also showed that Sivelestat (a popular HNE inhibitor) reduced cleavage 
of the probe but it was clear from the images that NIR fluorescence was still 
generated, presumably due to non-specific cleavage. Issues arise from the 
types of cell used by the group, A459 and RBL-2H3 cells (basophil line). The 
cells were first incubated with a solution of isolated HNE before adding the 
probe. This gives no indication of physiological levels of HNE in either cell 
line, or that the probe was not targeted by other related proteases present. No 







1.3.2 Substrate-based probes 
 
Figure 1.13. Structure of the self-quenching squaraine based optical probe 
10 (PBS, λEx = 605 nm, λEm = 658 nm when cleaved).70 
 
A peptide-based probe 10 was synthesised by attaching two squaraine based 
dyes (Figure 1.13).70 With a highly specific peptide sequence selected, β-Ala-
Ala-Pro-Ala-Lys-OBzl, with the two dyes conjugated at the amino terminus 
and on the primary amine of a lysine residue. This allowed for self-aggregated 
quenching due to the planarity of the dye. The authors report no kinetics of 
the HNE cleavage of the substrate, but they did confirm that the fluorescence 
intensity underwent a significant increase upon interaction with the enzyme. 
The end goal of the probe was not for use in vivo, but to adhere it to a glass 
slide for microarray analysis. The end goal was to adhere a mixture of different 
proteases to qualitatively state which enzymes are present in disease states by 





Probes 11 and 12 are two FRET (Forster resonance energy transfer) based 
‘activatable’ probes for HNE with each comprising two fluorophores 
connected by a peptide sequence (Figure 1.14).71 The optical probe 11 
comprises methoxycoumarin (donor, λEx/Em = 354/400 nm) and coumarin 343 
(acceptor, λEx/Em = 444/490 nm) which are connected by a PEG spacer to 
enhance the water solubility of the probe. The peptide sequence is cleaved 
between the two valine residues, and as the fluorophores are separated, 
illumination at 345 nm results in an emission at 400 nm, and this allowed for 






Figure 1.14. Non-cleaved optical probes 11 (non-cleaved λEx = 354 nm, λEm = 
490 nm) and 12 (non-cleaved λEx = 444 nm, λEm = 575 nm). The activity 
probes are cleaved between the two valine residues on the peptide sequences 
(orange dashed lines). 
 
Probe 12 comprises the fluorophores coumarin 343 (donor, λEx/Em = 444/490 
nm) and TAMRA (acceptor, λEx/Em = 456/575 nm), connected by a slightly 
modified peptide sequence to that of 11. It also contains a C15 alkane chain to 
increase the hydrophobicity of the probe, allowing it to dock to the cell’s outer 
plasma membrane. This permits the probe to only monitor the extracellular 
HNE activity, whilst securing the coumarin 343 fluorophore in place. As the 





carboxytetramethylrhodamine) moiety is released from the cell membrane 
and coumarin emission observed. The combined use of the two probes has 
elucidated for the first time that HNE activity is primarily active on the surface 
of the neutrophil, with biological studies carried out on murine neutrophils 
taken from a BAL sample.  
 
1.3.3 Always-on probes 
The peptide probe 13 contains four unnatural amino acids that had been 
selected as the substrate with the highest affinity towards HNE during a 
screening process developed by Kasperkiewicz (Figure 1.15).72,73 The C-
terminus was a diphenyl phosphonate moiety that irreversibly binds with the 
active site, and the N-terminus a long PEG chain capped with a biotin. The 
classical pairing of biotin-streptavidin allows for secondary labelling, as a 
streptavidin labelled fluorophore would bind the biotin enabling quantitative 
detection of HNE. There are several advantages of this type of probe, such as 
the ability to use a wide range of fluorophores conjugated to biotin; to allow a 
more accurate calculation of HNE and the ability to easily incorporate into gel 






Figure 1.15. (A) Optical probes for the detection of HNE 13 and 14. (B) 
Confocal images of a neutrophil labelled with optical probes interrogating the 
presence of serine proteases (red = HNE, light blue = Cat G, green = Pr3, 
dark blue = NSP4). Reprinted with permission from J. Am. Chem. Soc. 2017, 
139, 10115-101125. Copyright 2017 American Chemical Society.73,74 
 
Since the original research publication of the initial computational screening 
and cell research,73,75 the group itself has developed the scope of the probes to 
include the other serine proteases present in the neutrophil: cathepsin G, 
proteinase 3 and neutrophil proteinase 4 (Figure 1.15).74 Peptide sequences 
incorporating both natural and unnatural amino acids were chosen based on 





Met(O)2-Oic-Abu (depicted in Figure 1.15 A), NSP4 was hCha-Phe(guan)-Oic-
Arg, Cat G was His(Bzl)-Val-Pro-Phe and Glu(O-Bzl)-Lys(Ac)-hPro(Bzl)-Nva 
for Pr3.72 They developed four optical probes for each protease by altering the 
fluorophore: BODIPY, Cy3, Cy5 or Cy7 (16 probes in total). The Km of the 
labelled peptides were determined for all enzymes and the fluorophore on 
each probe were down selected based on their reactivity. The separation in the 
fluorescent signals from all dyes allowed for multiplexing of the enzymes for 
simultaneous staining (Figure 1.15, B). The final HNE imaging probe selected 
based on the best affinity was the Cy5 labelled peptide 14, which had a 
kcat/Km of 8.1 × 106 M-1s-1, but it also had affinity towards Pr3 (kcat/Km = 1.9 
× 105 M-1s-1). The research was transferred to live neutrophils and it is a major 
step forwards at imaging immune response in vivo. Interestingly, they found 
that the distribution of the proteases within the neutrophil was uneven, as can 
be seen in B of Figure 1.15 and using image analysis, determined the 
concentrations of the different enzymes.53 
 
Figure 1.16. Far-red probes 15 and 16 developed by Bunnett.76 
 
Further developing the chemistry from Kasperkiewicz, another group used 
the same diphenylphosphonate warhead, but incorporated only one or two 
amino acid residues in between the warhead and fluorophore (Figure 1.16), 





developed in the hope that they would be able to detect serine proteases, and 
after the synthesis, they were screened against a selection such as HNE, Pr3 
and trypsin, to confirm their selectivity. 15 labelled both Pr3 and HNE, but 16 
showed more affinity towards trypsin and thrombin. Probe 15 was taken 
through to further investigation, but mostly used in gel electrophoresis 
experiments, to determine the specificity and dosing requirements. A study 
on acute pancreatitis was conducted by creating a murine model of the disease 
through injecting the subjects with the oligopeptide caerulein to induce 
pancreatic secretion. The optical probe (20 nmol) in a mixture of DMSO and 
PBS (2:8, 100 µL) was then injected into the subjects and monitored. The 
negative controls showed no probe had been cleaved within the pancreas, 
whereas the pancreatitis models show strong levels of fluorescent signal. 
However, upon gel electrophoresis of cell lysate, no labelled enzyme was seen, 
indicating that it doesn’t irreversibly bind to the probe, or is highly non-
specific.  
Optical probe 17 (Figure 1.17) was also developed based on the 
diphenyphosphonate structure but modified to include a methyl thioether in 
the para position compared to the original 13.77 They found that using a 
mixture of natural and non-natural amino acids in their tripeptide recognition 
moiety gave a higher affinity towards HNE.  
The azido functionalised 17 without a dye had a kinac/Ki value of 3.9 × 105 M-
1s-1 (S,R,S), higher compared to its diastereomer (S,S,S) at 1.0 × 103 M-1s-1. Upon 
the addition of the fluorophore to form 17, the reactivity was reduced to 8.8 × 
104 M-1s-1, but still higher than (S,S,S). The inhibition of the activity of proteases 
by the three tripeptides showed them to be ineffective against cathepsin B and 
L, as well as thrombin and trypsin. The peptides were shown to be selective 
for HNE over its porcine counterpart, porcine pancreatic elastase, but no other 
serine proteases found in the neutrophil were tested and so it is difficult to 





in gel electrophoresis, where they saturated HNE with the probe before 
running the gel. The azido group gave rise to the ability to attach different 
fluorophores depending on which excitation and emission wavelengths were 
required. This was achieved by using Huisgen’s copper catalysed azide alkyne 
cycloaddition (CuAAc or click).78 This approach is appealing as it is high 
yielding, can be completed in mild conditions and enables the use of most 
fluorophores that are alkyne functionalised, but further testing would be 
required to determine if the peptide is specific enough for the enzyme 
targeted.   
 
 
Figure 1.17. Structure of the BODIPY based optical probe 17 (H2O, λEx = 509 
nm, λEm = 513 nm).70 
 
 
1.4 Previous research 
 
The Bradley/ Dhaliwal team has long been interested in HNE due to the 
damage that it can inflict on the lung by its overexpression, and so two 





were based on peptides with a known specificity towards HNE and were tri-
branched to induce self-quenching of the fluorophore, (carboxyfluorescein, 
λEx/Em = 490/525 nm). Upon peptide cleavage, the carboxyfluorescein 
molecules are released inducing a fluorescence signal (4-fold for 18, 2-fold for 
19).  
 
Figure 1.18. Peptide based activatable probes, 18 and 19, developed by 
Avlonitis79 (λEx = 490 nm, λEm = 525 nm). The peptide sequence is cleaved 
between the methionine and arginine residues. 
 
Further developed from this design was the optical probe 20 (NAP, Figure 
1.19). This has the same motif of self-quenching carboxyfluorescein moieties 
which fluoresce after the peptide sequence is cleaved (λEx/Em = 490/525 nm). 
The probe also includes a PEG motif as a spacer between the peptide sequence 
and the fluorophore. Carboxyfluorescein emits fluorescence in the green 
region, and so the turn-on activity of the probe can be difficult to distinguish 





(340–405 nm). Regardless of this, it is currently in first-in-man studies, with 
the potential to be used as a diagnostic probe.80  
 
Figure 1.19. Optical probe 20, NAP, with a similar design to 18 and 19, with 
the inclusion of a PEG spacer between the targeting motif and the fluorophore 
(λEx = 490 nm, λEm = 525 nm). 
 
The most recent publication was a tri-branched peptidic optical probe 21 
(Figure 1.20) designed to interrogate HNE in vivo.81 It has been demonstrated 
previously that HNE is anchored on the extracellular membrane of the 
neutrophil as well as within the azurophilic granule.71 This activity-based 
probe contains three fluorescein molecules that are each quenched with a 
methyl red. The activation of the probe is induced by cleaving off the methyl 
red labelled peptide, to relieve the tri-branched PEG type compound 
containing three FAM molecules, inducing an 8.5 fold increase in fluorescence. 
The activity of 21 was confirmed by adding it to neutrophil lysate, but by 
incubating the lysate in Sivelestat beforehand, no signal was observed, thus 
indicating the signal was HNE dependent. Following this, they also 
demonstrated a limit of detection as 10 nM, with no additional haemotoxicity 
to the solvent PBS. Confocal imaging of the probe in vivo within isolated 
human neutrophils was also used to confirm the signal uptake from the 
neutrophil. The neutrophils were also incubated with two inhibitors, α-PI and 
Sivelestat, before the addition of 21. The method of inhibition of α-PI involves 





membrane and inhibits intracellular HNE. By alternating these, the 
fluorescence was only present when α-PI was used, inferring the probe 
detected only intracellular levels of HNE. The addition of the membrane stain 
Calcein was used to confirm the co-localisation of vesicles and HNE, 
demonstrating that phagolysosomes contained active HNE.  
 
 
Figure 1.20. The ‘silent’ optical HNE probe 21 from Craven.81 The probe is a 
tri-branched peptide with the fluorophore 5,6-carboxyfluorescein (green, FAM) 







1.5 Aim of the thesis 
 
The aim of this thesis was to develop optical probes for the identification and 
visualisation of elevated levels of HNE. This would aid rapid diagnosis of 
selected pulmonary diseases in vivo. In short, this was to be achieved by: 
• Synthesis of multiple biocompatible fluorophores on gram scale  
• Synthesis of several HNE inhibitors, and the generation of optical 
probes through conjugating the molecules to fluorophores 
 
The optical probes generated were then evaluated for their biological 
applicability by measuring cytotoxicity, affinity towards HNE and live cell 










The use of fluorophores has been long established as a method to elucidate 
mechanisms of biological processes.82,83 Several hundred, if not thousands of 
different fluorophores have been reported, with fluorescent properties over a 
wide variety of wavelengths from across the spectrum.15,84,85 The sheer 
quantity gives great scope for chemists and biologists alike to select the 
optimal molecules for imaging while tuning the inherent properties of the 
fluorophore such as quantum yield, Stokes shift, excitation and emission 
wavelengths to the biological question under investigation.  
 
Scheme 2.1. The synthetic pathway for the two regioisomers of 
carboxyfluorescein: 5-carboxyfluorescein (22) and 6-carboxyfluorescein (23). 
Reaction conditions: ZnCl2, Δ. 
 
Carboxyfluorescein (22, 23) is a derivative of fluorescein and can be easily 
synthesised by incorporating a carboxylic acid group onto the naphthalic 
anhydride, however this gives a mixture of regioisomers (5 & 6, Scheme 2.1). 
Carboxyfluorescein is easily incorporated into imaging probes, as the free 
carboxyl group can be conjugated to a variety of biologically targeting 
moieties through amide bond formation. Altogether, these properties make it 





One shortcoming of fluorescein based compounds is the fluorescent emission 
resides in the same region of the spectrum as tissue autofluorescence, possibly 
making it difficult to distinguish background from probe fluorescence.24 Far-
red fluorophores (>650 nm) can be used to avoid this issue as tissue 
autofluorescence is negligible in this region of the spectrum. 
Cyanine dyes are made up of a conjugated backbone with two indole capping 
groups, although other aromatic heterocycles have been used (Figure 2.1). The 
wavelengths absorbed and emitted by the cyanine dyes are ‘tuneable’ by 
altering the unsaturated carbon chain length from 3 carbons (550-570 nm) to 5 
(650-670 nm) to 7 (750-780 nm). Due to the extended conjugation present in 
cyanine dyes, they are lipophilic, but this can be remedied by modifying the 
structure to incorporate hydrophilic functional groups (e.g. sulfonates). 
 
Figure 2.1. Basic structure of cyanine dyes (left) where n = 1, 2 or 3. Basic 
pentamethine dye structure used in this thesis (right), where R and R’ are 
alkyl groups of varied lengths and functional groups. 
 
Pentamethine, or Cy5, dyes (Figure 2.1) have been frequently used for imaging 
biological processes as emission is in the far-red region of the spectrum (630-
700 nm), thus having the ability to enable contrast against tissue 
autofluorescence, which frequently occurs in the ‘green’ region of the 
spectrum (510-560 nm).86 They also have relatively high extinction coefficients 
and reasonable quantum yield (c.a. 0.25), giving them ’good brightness’.  
 






For the synthesis of optical probes to allow the in vivo detection of human 
neutrophil elastase (HNE) within the lungs, a fluorophore had to be 
conjugated to the targeting moiety. With this in mind, the aims of this chapter 
were to synthesise several biocompatible fluorophores with a range of 
wavelengths, on a large scale.   
 
2.3 Preparation of single isomers of 5 and 6-
carboxyfluorescein  
 
Carboxyfluorescein is a common commercially available fluorophore, 
typically sold as a mixture of regioisomers. It is preferable to have single 
isomers of dyes to aid purification of imaging compounds, due to possible 
resulting diastereomers. Additionally, the presence of just a single isomer is 
advantageous for compounds targeting clinical use, simplifying the regulatory 
aspects. Previously in the group, a simple procedure was used to separate the 
two regioisomers of carboxyfluorescein, in addition to forming the active 






Scheme 2.2. Synthetic route to 5 and 6-carboxyfluorescein diacetate N-
hydroxyl succinimide esters, 25 & 26. Reaction conditions: i) Ac2O, pyridine, 
110 °C, 3 h, 100% conversion by HPLC; ii) NHS, DIC, DCM, 0.5 h, yield 25 
36%, 26 24%. 
Separation by column chromatography took place after two steps: acetylation 
of the phenols followed by activation of the carboxylic acid. The two phenol 
functionalities were deprotonated by pyridine driving the lactone formation, 
with the phenolate anions reacting with acetic anhydride, giving the phenol 
acetates (Scheme 2.3). Using acetic anhydride in large excess ensures this 
occurs on both phenols to generate 24.  
 
Figure 2.2. HPLC ELSD traces of 5(6)-carboxyfluorescein (green trace) and 






Scheme 2.3. Proposed mechanism of acetylation of the phenols on 5(6)-
carboxyfluorescein. 
 
In the second step, activation of the carboxyl group through the addition of 
N,N’-diisopropylcarbodiimide (DIC) and subsequent reaction with N-
hydroxysuccinimide (NHS) generates a N-hydroxylsuccinimide active ester. 
This ester allows for nucleophilic attack by an amine to give an amide. The 
carboxyl group reacts with DIC to generate the O-acylurea. This is attacked by 
the nucleophilic hydroxyl group of the NHS, to generate the active esters 25 






Scheme 2.4. Formation of N-hydroxylsuccinimidyl esters of 5 & 6-
carboxyfluorescein diacetate, 25 and 26. 
 
The consequence of both acetylation and activation of carboxyfluorescein 
makes it possible to separate the two isomers using simple flash column 
chromatography. The products were separated using an isocratic gradient 
with the solvent system toluene and ethyl acetate to generate the activated 
isomers in yields of 36% for 25 and 24% for 26. Purity was assessed by HPLC 
where the isomers were shown to be successfully separated (Figure 2.3), the 
reaction was scaled up to 40 mmol (15 g) with similar yields. It was possible to 






Figure 2.3. RP-HPLC traces of 5-carboxyfluorescein NHS ester (blue), mixture 
(red) and 6-carboxyfluorescein NHS ester (orange), confirming their 
separation (ELSD channel), analysed by analytical HPLC. 
 
Due to the presence of acetyl groups on the phenolic hydroxyl groups of 
carboxyfluorescein, the final compounds 25 and 26 were more fluorescent after 
deprotection during the conjugation chemistry (Figure 2.4 shows one isomer). 
 
Figure 2.4. Absorption (yellow, λEx = 494 nm) and emission (green, λEm = 
521 nm) spectra of 6-carboxyfluorescein NHS ester after the addition of 
triethylamine (excitation at 480 nm) and emission before the addition of 
triethylamine (blue, λEm = 515 nm). 1 µM solutions were made up of 10% 






2.4 Synthesis of pentamethine dye 27 
 
To generate several optical probes in the far-red region of the spectrum, a far-
red dye was required, and on large scale to allow sufficient amount of probe 
for testing. Several Cy5 dyes are available but are expensive (Alexafluor 647, 1 
mg = £302, October 2018),88 and as such, synthesis of a dye was required. The 
Cy5 27 (Figure 2.5) was selected as it had been incorporated into several optical 
probes with clinical applications.89–91 The dye has several sulfonate groups 
increasing its solubility, in addition to containing a carboxylic acid at the end 
of a six carbon chain, available for conjugation to an amine.  
 
Figure 2.5. Pentamethine dye 27. 
 
The most common method of disconnection for cyanine dyes is between the 
two head groups. The indoles can be identical to generate a symmetrical Cy5 
dye, or different, such as in 27, for an unsymmetrical Cy5.  
 







Indole 28 was synthesised by a Fischer indole reaction, using 4-
hydrazinobenzenesulfonic acid and 3-methylbutan-2-one under acidic 
conditions (Scheme 2.5). This afforded 28 in a high yield (78%) and was easily 
purified through precipitation with Et2O as a potassium salt (Scheme 2.6).  
 
Scheme 2.6. Postulated mechanism for Fischer Indole synthesis of indole 28 
under acidic conditions, where the indole was drawn as a sulfonate for ease.92 
 
Compound 28 was used in two ways, both with SN2 quaternisation reaction of 
the amine group of the indole. Thus compound 28 was added to neat 
bromoethane and heated to reflux for 24 hours, until complete conversion seen 






Scheme 2.7. Synthesis of indoles 29 and 30. Reaction conditions: i) reflux, 
24 h, 98%; ii) DMF:MeCN (9:1), 150 °C, 4 h, µw, 60%. 
 
For 30, indole 28 was reacted with 6-bromohexanoic acid diluted in a mixture 
of DMF and acetonitrile (9:1), with the reaction taking four hours in a 
microwave reactor at 150 °C. Previously, it had been found that, conventional 
heating required 48 hours for good conversion. Indoles 29 and 30 were 
purified by removal of the reaction solvent before re-dissolving the crude 
product in a minimal amount of acetonitrile, and crystallisation from diethyl 
ether.  
Upon formation of the functionalised indoles, 29 was added to malonaldehyde 
bis(phenylimine) hydrochloride and heated to reflux to form the conjugated 
anilide intermediate 31 (Scheme 2.8). Purification of this intermediate was time 
consuming as the excess bisphenylamine had to be removed through rigorous 
washing. The crude intermediate was dried at 40 °C with a vacuum overnight 






Scheme 2.8. Postulated mechanism for the formation of 31. Reaction 
conditions: i) AcOH, Ac2O, NaOAc, reflux, 3 h, 26% after purification. All 
sulfonate groups are shown as sulfonic acids for simplicity. 
 
 Indole 29 was reacted with 30 and sodium acetate in a solvent system of acetic 
anhydride and acetic acid (2:1) to generate the conjugated Cy5 dye (Scheme 
2.9). The reaction could be monitored by HPLC, as the formation of the 
product had a wavelength of 650 nm (Figure 2.6). After the reaction was 
complete, the crude product was analysed by HPLC and LCMS and shown to 
contain 27 in addition to the two symmetrical dyes of the two functionalised 
indoles (32 and 33, Figure 2.7). The crude mixture was purified by reverse 







Scheme 2.9. Cy5 dye synthesis: i) AcOH: Ac2O (2:1), NaOAc, reflux, 3 h, 
26% after purification. Mechanism of conjugation of indole 30 and 31 to form 
pentamethine dye 27. 
 
 
Figure 2.6. HPLC trace of the reaction mixture (Scheme 2.9) for the 







The dye was synthesised on a large scale, whereby 1.4 mmol of one indole was 
used to generate some 0.5 g of the final Cy5 dye after purification. The 
excitation and emission of the dye were examined as having an excitation 
maximum of 650 nm and emission maximum 666 nm (Figure 2.8).  
 
Figure 2.7. The two symmetrical Cy5 dyes 32 and 33 produced as by-




Figure 2.8. Absorption (blue) and emission (red) spectra of Cy5 27 in PBS (1 
µM), with both sets of data normalised to 1. Emission recorded after excitation 









2.5 Synthesis of pentamethine dye Cy5** 
 
Cy5** (34, Figure 2.9) is an asymmetric, water soluble pentamethine dye that 
has been incorporated into several optical probes and used in vivo. Patents 
have been filed for optical probes containing the dye with the aim of using 
them in several diseases, such as dysplasia, tumours with high c-Met 
expression and lymphomas.93–95 A study was published in 2015 detailing the 
use of a Cy5** labelled peptide in patients for the location of cancerous polyps 
in the colon.96 The combination, highlights the versatility of the dye and its 
advantageous application in humans.  
Cy5** has been used frequently because of its desirable properties, such as 
high water solubility, good brightness, and photostability under ambient 
light.96,97 In particular, the dye has been shown to achieve clearance from the 
body, predominantly through the renal system. The precedent in clinical use 
made it attractive to synthesise and use in optical probes for HNE detection. 
 
 






In order to synthesise the trisulfonated indole 39 (Scheme 2.12), a sulfonated 
ketone was required that could be incorporated into the indole (37, Scheme 
2.10). The alpha proton of acetoacetate 35 was deprotonated by a hydride, and 
the enolate produced used to attack 1,4-butane sultone inducing ring opening 
and creating a terminal sulfonate group on 36.  
 
 
Scheme 2.10. Synthesis of intermediate 37. Reaction conditions: i) NaH, 
DMF, 0 to 5 °C for 1 h, then 50 °C for 18 h; ii) NaOH, H2O, 90 °C, 18 h, acid 
workup with HCl. 
 
The ethyl ester was removed by saponification with sodium hydroxide and 
loss of CO2 to generate 37, which was carried through to the next reaction 
without purification (Scheme 2.10). Base mediated hydrolysis of the ester 
occurs to generate a carboxylic acid (Scheme 2.11), which then loses CO2. The 
reaction induces decarboxylation and the product, an enolate, tautomerises 






Scheme 2.11. Proposed mechanism of formation of 37. 
 
Sulfonated ketone 37 then underwent Fischer indole chemistry with 4-
hydrazinobenzenesulfonic acid to generate the disulfonated indole 38 in a 
similar fashion to Cy5 27 (Scheme 2.12). The product required purification, 
before reacting with 1,4-butane sultone in excess, to force completion of the 
SN2 quaternization on the amine. The yield of trisulfonated 39 was moderate 
(51%) in comparison to previously synthesised indoles and required 48 h for 
the reaction to proceed. It was also attempted in a microwave reactor, but the 






Scheme 2.12. Final synthetic steps towards trisulfonated indole 39. Reaction 
conditions: i) AcOH, 105 °C, 12 h, 41% from 35 to 38; ii) dimethyl 
acetamide, reflux, 24 h, 51%. 
 
With both indoles in hand, the synthesis was completed by conjugating the 
two indoles (Scheme 2.13). The carboxyl modified indole 30 to an alkene, 
which undergoes nucleophilic attack on a bisphenylanilide to form 40. Upon 
purification, 40 was reacted with indole 39 and heated to reflux. As with Cy5 
27, the reaction was monitored by HPLC at 650 nm, where the formation of 
product 40 could be seen, alongside the two symmetrical Cy5 dyes (Figure 
2.10). After the reaction was complete, the crude product required preparative 







Scheme 2.13. Final steps towards the synthesis of Cy5** 34. Reaction 
conditions: i) Ac2O, acetic acid, reflux, 4 h; ii) Ac2O, acetic acid, NaOAc, reflux, 
3 h, 12% after purification. 
 
 
Figure 2.10. Two symmetrical Cy5 dyes 41 and 33 produced from the final 
conjugation reaction. 
 
Dye 34 was analysed by UV-vis spectroscopy and fluorimetry to identify its 
excitation and emission maxima. The excitation maximum was 666 nm and it 
had a far-red emission at 673 nm upon excitation at 650 nm (Figure 2.11), 






Figure 2.11. Absorption (blue, λEx = 666 nm) and emission (red, λEm = 673 
nm upon excitation at 660 nm) spectra of Cy5** 34 in PBS solution (1 µM), 





Optical medical imaging requires dyes that can be used within the biological 
environment and biological window, and with functional groups available for 
reacting with the targeting moiety. Herein, several water-soluble dyes were 
successfully synthesised containing carboxyl groups available for conjugation 
to a recognition element that targets HNE.   
The pentamethine dye Cy5** whilst synthesised on a large scale in industry, it 
was not reported in large scale elsewhere. A paper referenced during the 
synthesis had a starting mole of 0.3 mmol, and yield of 11%, whereas this thesis 
used 1.6 mmol and a yield of 12%.98 Cy5 27 was synthesised in a similar 
manner to Cy5** and whilst literature used a larger scale, it didn’t report the 
yield for this particular dye, but the yield of another non-symmetrical dye was 
5%.99 Another literature search gave a patent stating their yield as 22%, but 





The mixture of regioisomers for 5 and 6 carboxyfluorescein were successfully 
modified with acetyl groups and activated allowing separation of the isomers 
in yields of 36% and 24%. Two variations of water soluble asymmetric 
pentamethine dyes, 27 and 34, were synthesised and purified using reverse 











Research into the overexpression or overactivation of human neutrophil 
elastase (HNE) has implicated its involvement in a wide range of diseases, 
making it an ideal drug target, particularly for pulmonary diseases.101,102 The 
Moreira group has developed a portfolio of HNE inhibitors based on a 
common binding scaffold (Figure 3.1).103 Screening a large range of aryl 
groups based on inhibitor 42, they found that compounds 2-
mercaptobenzoxazole 43 and 2-mercaptobenzothiazole 44 had the highest 
affinity towards HNE.  
 
Figure 3.1. The key motif found in the HNE inhibitor, 42, and the structure of 
the first generation inhibitors 43 and 44, which displayed a high affinity for 
HNE.103 
 
The inhibition constants, or Ki, values for the inhibitors were found to be as 
low as 0.34 nM (43) and 0.50 nM (44). In addition to the compounds having 
high affinity for HNE, they also showed little to no affinity for other related 





Both showed no inhibition when incubated with proteinase 3 (Pr3) but 43 had 
a kobs value of 4080 M-1s-1 for cathepsin G (Cat G), much larger in comparison 
to 44 at 29.6 M-1s-1.  
The postulated mechanism of inhibition by the oxo-β-lactams involved 
nucleophilic attack by the hydroxyl group of the serine present within the 
active site (Scheme 3.1). This induces ring opening of the azetidine-2,4-dione 
and formation of an ester bond between one of the carbonyl groups and the 
serine residue. The stability of this intermediate can be dependent on the R 
group on 42. 
 
Scheme 3.1. Postulated mechanism of inhibition by the oxo-β-lactams with 
HNE modification of Ser195 within the active site of the protease.  
 
Another inhibitor of HNE generated was probe 45, with a sulfonyl group 
(Figure 3.2), with a Ki determined to be 0.63 nM and kon 1.46 × 106 M-1s-1, it also 
had a higher affinity towards HNE than other serine proteases.104 The kon value 
for 45 and Pr3 was 4.99 × 103 M-1s-1 but much lower for Cat G at 41.4 M-1s-1, 
indicating that the selectivity was big enough to take it through for further 
testing. The in vitro data led to in vivo murine studies to determine the efficacy 
of the molecule as a drug. However, the half-life of the probe was very short, 
showing poor stability in PBS (t1/2 = 1 h), and faring even worse in human 
plasma (t1/2 = 6 min) and led to the inhibitor being discarded as a potential 






Figure 3.2. Second generation inhibitors based upon the oxo-β-lactam 
motif.104,105 
 
The same group also developed an oxo-β-lactam 46 that is conjugated to an 
umbelliferone scaffold, and encapsulated it into starch nanocapsules to allow 
slow release of the inhibitor as a treatment option for psoriasis, another disease 
where HNE has been demonstrated to be at high levels.36,105,106 The inhibitor 
was shown to have an IC50 of 0.67 nM, and studies were used to determine the 
concentration required for the most effective treatment against HNE 
damaging the upper dermal layer of skin.  
Another set of HNE inhibitors with incorporated fluorophores and oxo-β-
lactam warhead were compounds 47 and 48 (Figure 3.3). These inhibitors were 
formed by reacting azide functionalised fluorophores with a propargylated 
oxo-β-lactam in a copper catalysed azide-alkyne cycloaddition (CuAAC).  
 
Figure 3.3. Fluorescent compounds with the same warhead from Ruivo et al., 
targeting the detection of HNE.107 
 
The probes were analysed against HNE to generate their IC50 values, 





Interestingly, they only screened 47 against other serine proteases including 
Pr3 (IC50 = 3 µM), thrombin (1 µM) and chymotrypsin (23 µM) but not Cat G. 
The probes were shown to bind to HNE by gel electrophoresis and were used 
to elucidate enzyme activity in situ, by indicating the presence of HNE within 
neutrophils. 
The facile method of altering the R group present on compound 42 without a 
evident loss of activity makes this an attractive HNE targeting element to be 
incorporated into optical probes.104  
 
3.2 Aims of chapter 3 
 
HNE is a serine protease found within the azurophil granules in neutrophils 
and mis-regulation has been correlated with several pulmonary diseases, with 
high levels of the enzyme in the lung causing irreversible tissue damage. Many 
pulmonary diseases can be difficult to diagnose due to ambiguous symptoms, 
particularly differentiating between bacterial infection and an autoimmune 
response in diseases such as COPD and fibrosis.   
The aim of this chapter was to generate several fluorescent optical probes with 
a range of wavelengths to allow the detection of the presence of HNE in vivo. 
To interrogate the correlation between structure and affinity, two types of 
spacers between the oxo-β-lactam and fluorophore were used. The optical 
probes were evaluated for their activity and affinity towards HNE, incubated 
with neutrophils and used to determine the presence of HNE with the target 
of developing in vivo optical imaging of neutrophils for rapid disease 






3.3 Synthesis of aromatic oxo-β-lactam based 
optical probes   
 
The synthesis of the oxo-β-lactam motif was adapted from the work of Moreira, 
starting from N-Boc-aminobenzylamine that undergoes cyclisation with 
diethylmalonyl chloride forming lactam 49 (Scheme 3.2).103 
 
Scheme 3.2. Synthesis of HNE targeting compound 50. Reaction conditions: 
i) TEA, dioxane, -10 °C to rt, 18 h, 25%; ii) 4 M HCl in dioxane, 6 h, quant. 
 
The initial addition of the amino group to the acid chloride could be achieved 
without base, but for the second substitution, an equivalent of base was 
required to ensure reaction. The low yield (25%) is due to the majority of the 
compound forming a dimer, whereby the diacid chloride undergoes two 
consecutive intermolecular reactions instead of the required second 
intramolecular cyclisation (Figure 3.4).  
 
Figure 3.4. Main product of the reaction in Scheme 3.2. 
 
The reaction was initially carried out using the same reaction conditions as in 
the literature107 but the product was obtained in poor yield (4%). The yield was 
increased by decreasing both the temperature and base equivalents, from rt to 
0 °C, and from 3.7 equivalents to 2.4. The product and by-product were easily 





cleave the Boc protecting group using acidic conditions, with the product 
forming in a quantitative yield without requiring further purification.  
The primary amine could then undergo amidation with a fluorophore. This 
was firstly completed using 5-carboxyfluorescein (Scheme 3.3).  
 
Scheme 3.3. Synthesis of the carboxyfluorescein based optical probe 51. 
Reaction conditions: DIPEA, PyBrOP, DMF, 24 h, 31%. 
 
The activation of the carboxylic acid on the fluorophore was achieved by the 
coupling reagent PyBrOP, to generate in situ an acid bromide, a labile leaving 





Scheme 3.4. Mechanism of activation of 5-carboxyfluorescein using PyBrOP. 
 
The optical probe 51 was formed in a moderate yield of 31% after purification, 








Figure 3.5. Absorption (yellow) and emission (green) spectra of 51. Solutions 
were 1 µM in PBS (pH 7.4), and the data normalised.  
 
Subsequently, the inhibitor 50 underwent amidation with Cy5 dye 27 (Scheme 
3.5). The carboxylic acid group on the dye also required activation in situ 
before the addition of the amine. In this particular reaction, the preferred 
coupling reagent was HSPyU that forms a succinimide ester (Scheme 3.6). 
 
Scheme 3.5. Generation of NIR optical probe 52. Reaction conditions: i) 






The activation of the dye was monitored by HPLC, as the retention time shifts 
significantly upon formation of the succinimide ester and after which the 
inhibitor (50) was added. The amidation was monitored until the activated dye 
was shown to be fully consumed, after which the solvents were removed, and 
the product purified by reverse phase column chromatography.    
 
Scheme 3.6. Activation mechanism of the cyanine dye 27 with HSPyU. 
 
The excitation and emission spectra of probe 52 was then analysed (Figure 3.6). 
Probe 52 underwent a slight bathochromic shift from the original Cy5 dye 27 
by 2 nm, the new excitation wavelength being 649 nm with the emission 







Figure 3.6. Absorption (blue) and emission (red) spectra of probe 52. 
Solutions were 1 µM in PBS, and the data normalised. 
 
3.4 Synthesis of oxo-β-lactam optical probes 
containing an ethyl spacer 
 
The second oxo-β-lactam based HNE inhibitor generated contained an ethyl 
moiety linking the warhead to the fluorophore in place of the phenyl group on 
50. The synthesis was similar in that another Boc-protected primary amine was 
used for cyclisation with the diacid chloride (Scheme 3.7).  
 
Scheme 3.7. Synthetic route for HNE targeting compound 54. Reaction 
conditions: i) TEA, dioxane, -10 °C to rt, 18 h, 22%; ii) 4 M HCl in dioxane, 4 
h, quant. 
 
The cyclisation reaction was initially achieved at room temperature, but this 





22%. The Boc protecting group was then removed using hydrochloric acid, to 
unmask the primary amine, for amidation with a fluorophore.  
The first fluorophore to be used was the protected and activated 5-
carboxyfluorescein 25 (Scheme 3.8). This was carried out using DIPEA (9 equiv) 
as the phenols were deprotected in-situ by deacetylation in addition to the 
amidation reaction.  
 
 
Scheme 3.8. Synthetic route to the generation of carboxyfluorescein based 
probe 55. Reaction conditions: DIPEA, DMF, 18 h, 21% after purification. 
 
In a similar fashion to probe 49, optical probe 53 required purification using 
reverse phase chromatography. The excitation maximum of 53 was 494 nm, 







Figure 3.7. Absorption (yellow) and emission (green) spectra of probe 55. 
Solutions were made up of PBS (pH 7.4, 1 µM), and the data normalised. The 
emission was collected with excitation at 480 nm.  
 
The subsequent fluorophore used was Cy5, and in the same fashion as probe 
52, with the carboxylic acid activated in situ using HSPyU (Scheme 3.9).  
Amidation was likewise monitored by HPLC and compound 56 was purified 
using reverse phase preparative HPLC to obtain the optical probe in 45% yield.  
Scheme 3.9. Final synthesis steps of probe 56. Reaction conditions: i) 






Probe 56 was then analysed to show its excitation and emission maxima, at 650 
nm and 666 nm respectively (Figure 3.8), confirming emission in the far red 
and in the desired optical window.  
 
Figure 3.8. Absorption (blue) and emission (red) spectra of 56. 1 µM 
solutions were made up in PBS (pH 7.4), and the data normalised. Emission 
was recorded after exciting at 630 nm. 
 
With four optical probes in hand, the next step was to evaluate their biological 
properties and potential as imaging agents for detecting HNE in vivo.  
 
3.5 Biological evaluation of optical probes 
 
The optical probes required evaluation to indicate whether they were suitable 
in a biologically relevant setting. This involved determining the stability, 
affinity towards HNE, its toxicity towards mammalian cells, and the 






3.5.1 IC50 determination of optical probes  
The half maximal inhibitory concentration, or IC50, is used to determine 
relatively how potent a drug is. There are many methods that can be used to 
determine an IC50. In this thesis, it was achieved using the well-known 
chromogenic peptide-based substrate, N-methoxysuccinyl-alanine-alanine-
proline-valine-amido-4-methyl coumarin (MeOSuc-AAPV-AMC, Scheme 
3.10). 
 
Scheme 3.10. HNE substrate N-methoxysuccinyl-alanine-alanine-proline-
valine-amido-4-methylcoumarin 7 and the mechanism of fluorescence upon 
peptide cleavage. 
 
7 is a tetrapeptide which has been modified on both terminals. The N-terminus 
has been capped with methoxy succinate and the C-terminus reacted with the 
fluorophore amino-4-methylcoumarin. The enzyme HNE cleaves the amide 
bond between the peptide and fluorophore, releasing coumarin, enabling a 
fluorescent signal to be detected as a signal of enzyme activity.  
The enzyme was incubated with a variety of concentrations of the probes for 
30 minutes, after which the substrate was added. The initial velocity of the 
reaction was calculated and plotted against the inhibitor concentration to 
determine at which concentration the enzyme activity was reduced by 50%, 
when compared to the enzyme alone (negative control). The graphs are shown 






Figure 3.9. IC50 graphs of optical probes 51 (A), 52 (B), 55 (C) and 56 (D). 
Data was collected using a plate reader and measuring fluorescence of 
substrate 7. The optical probes were incubated with HNE for 0.5 h before the 
addition of the substrate, at various concentrations (n=3, except for A where 
n= 2).     
 
Interestingly, the two carboxyfluorescein based probes had lower IC50 values 
than the Cy5 based probes, probe 51 having an IC50 of 37 nM and 55 an IC50 of 
25 nM (Figure 3.9, A and C). The two Cy5 probes (52 and 56) still had 
respectable IC50 values of 59 and 50 nM, indicating good affinity towards the 
enzyme.  
This confirmed the addition of the fluorophores didn’t strongly affect the 
activity of the oxo-β-lactam scaffold towards HNE and provided some 






3.5.2 Ki determination for the optical probes 
The Ki was to be determined in a similar manner as the IC50 values (Figure 3.9) 
but without incubating the enzyme and probes before the experiment. This 
was to determine the rate of inhibition, however, there were many issues in 
replicating this data. When using the same stock of serial dilutions varying 
results were observed, with some showing strong inhibition, and some almost 
none. This was a common occurrence for all probes, making reproducible Ki 
data problematic. It is also possible that the measurable inhibition was playing 
a complicated role  
 
3.5.3 Stability of optical probes in solution 
The difficulties in collecting reliable data for the Ki constants led to the stability 
of the probes in aqueous media being examined, as the decrease in activity 
could be a cause in the change in progress curves over time. Additionally, 
stability of the compounds in biological environment is also a significant 
requirement of a probe used in a clinical setting.  
The optical probes were incubated at 37 °C in PBS and analysed by HPLC over 
24 hours to determine the level of degradation (Figure 3.10). Most of the probes 
were relatively stable under these conditions, except for probe 51, which had 
a half-life of 22 hours. These values indicate that the stability of the probes in 
PBS had no bearing on the difficulties in determining their Ki values, as the 
solutions were only made up for a few hours. However, they do show that the 
probes robustness could allow for clinical use due to their reasonable lifetime 







Figure 3.10. Stability study of optical probes (60 µM) in PBS at 37 °C (n=1). 
Degradation of the samples were analysed by analytical HPLC at 254 nm for 
51 and 55 (A and C) or 650 nm for 52 and 56 (B and D). 
 
A similar experiment was completed by incubating the optical probes in 






Figure 3.11. Degradation of optical probes (60 µM) over time at 37 °C in 
DMEM media (n=1). The formation of by-products and degradation was 
monitored using analytical HPLC at 254 nm for 51 and 55 (A and C) or 650 
nm for 52 and 56 (B and D). 
  
The probes 51 and 52 exhibited longer half-lives than 55 and 56, with t1/2 
values falling between 1 and 2 hours, in comparison to probes 55 and 56, where 
degradation from the initial measurement was determined to be 60% by-
product. They exhibited almost instantaneous degradation, as HPLC traces of 
almost all compounds at t=0 h had large amounts of by-product, which was 
absent in the PBS traces of the same stock solutions (Figure 3.12). The 
instability of the optical probes in media is unsurprising due to the number of 
enzymes present in the solution, as well as the fact it is unnecessary, as 
neutrophils do not require media after isolation, if anything the media would 







Figure 3.12. Example of the observed ‘instant degradation’ of an optical 
probe in media. The probe 52 at t= 0 h, in PBS (blue) and media (red), 
analysed by HPLC in the 650 nm channel. 
 
3.5.4 Gel electrophoresis of the optical probes and human neutrophil 
elastase 
To confirm that a covalent bond was formed between the probes and HNE, 
the probes were incubated with enzyme for 5 mins before undergoing gel 
electrophoresis. The gel was first imaged in different fluorescent channels to 
visualise the presence of the fluorophores, before being stained with 






Figure 3.13. Imaging of human neutrophil elastase incubated with the optical 
probes 51, 52, 55 and 56 by SDS-PAGE. Imaged using coommassie blue 
staining (A is in greyscale and C), the fluorescein channel (B) and the 625 nm 
channel (D),  (-/+) HNE with no optical probes, and (-/+) optical probes 
without HNE. The outermost lanes are kaleidoscope ladder from Biorad. 
 
Interestingly, the two far red probes can be distinguished (Figure 3.13 D) but 
no fluorescence was detected from the optical probes using the 495 nm channel 
(Figure 3.13 C), which may have been caused by a number of factors. Possible 
reasons include: the concentration of the optical probes was too low at 2.5 µM, 
the fluorophore had been photobleached and were not bright enough for a 
detectable fluorescent signal or the ester bond formed was destroyed by the 
denaturation technique, but unlikely as the far-red probes were stable. Further 
research would be required to elucidate the cause.  
3.5.5 Toxicity of optical probes 
As the probes were designed with the intention for use in vivo, a vital 





common methods of assessing cytotoxicity is an MTT assay but this is 
primarily used on tumour cells and would be a skewed representation of 
cytotoxicity on the epithelial cells within the lungs. As such, a different cell 
viability study was targeted, a haemolysis assay, as the cells targeted are red 
blood cells, and haemolytic activity would prevent clinical use of the optical 
probes.  
The assay was achieved by incubating the probes for an hour at 37 °C with 
erythrocytes at two different concentrations and monitoring the concentration 
of porphyrin released after an hour, compared to a known standard curve 
(Figure 3.14). This was repeated with three samples from different volunteers 
and on different days.  
 
Figure 3.14. Haemolysis assay of the optical probes 51 (green), 52 (orange), 
55 (blue) and 56 (purple), at two concentrations 50 nM and 5 µM, with the 
data compared to a standard curve of controlled haemolysis, n=3.  
 
The haemolysis assay determined that all probes had a cytotoxicity of less than 
2% at 5 µM, a concentration ten-fold higher than needed, making them 






3.5.6 Confocal imaging of optical probes  
After confirming the optical probes bound to HNE and could be detected with 
fluorescent imaging after gel electrophoresis (Figure 3.13), the next step was 
to image the probes on human neutrophils. This was achieved by first 
isolating the neutrophils from a donated whole blood sample using a 
previously stated protocol.24,108 The neutrophils were then incubated with a 
calcium ionophore to activate them before adding the optical probes for 10 min. 
The cells were then imaged using confocal microscopy. In addition to the 
probes, they were also stained with Hoechst 33342, a UV-active dye that is 
specific for the nucleus (Figure 3.15). In imaging 55, an additional imaging 
agent was used, an HNE specific antibody with a far-red fluorophore. This 
allowed for confirmation of staining the enzyme, as the two HNE probes 
would be seen to co-localise. 
                                                 
   The human neutrophils were sourced ethically, and their research use was in accordance with the 






Figure 3.15. Live confocal imaging of activated human neutrophils incubated 
with the optical probes (500 nM, 10 min) and nuclear stain Hoescht 33342 
(blue, 405 nm laser line). Image (A) was stained with 51 (green, 488 nm laser 
line), (B) was stained with 52 (red, 630 nm laser line), (C) was stained with 
55 (green), in addition to an HNE specific antibody (red) and (D) was stained 
with 56 (red).  
 
3.5.7 Flow cytometry of 55 
The confocal images confirm uptake of the probes by neutrophils, but flow 
cytometry provides a quantitative method. Neutrophils were isolated from 
human blood using a previously described method to purify whole blood by 
fractional density with Percoll, then resuspended in PBS.108 The cells were 
separated into various wells: a control with no activation or probe, and cells 
activated and cells without activation. Two different concentrations of optical 
probes were analysed to compare the concentration effect as well as the effect 
of activation of the neutrophils (Figure 3.16). In addition to the neutrophil 





to confirm the cells were neutrophils. The cells were incubated with probe 55 
for one hour at 37 °C, and half of which were activated using a tripeptide, 
fMLF, a commonly used activator of leukocytes. 
 
Figure 3.16. Labelling of neutrophils with probe 55. Flow cytometry density 
plots of neutrophils after being incubated with a labelled CD66b antibody (15 
min) and optical probe 55, whereby the boxed data indicate a positive result. 
A and D represent a population of neutrophils after incubation with labelled 
CD66b, with a control population (A) and an activated population with 1 µM 
fMLF (D); (B) and (E) are neutrophils incubated with 250 nM 55, where E has 
also been incubated with activation agent fMLF; C and F are neutrophils after 
0.5 h incubation with 500 nM 55, where F was also incubated with the 
activation agent fMLF. All density plots had a cut off after 10 000 counts, with 
n = 1. 
 
The control density plots (Figure 3.10 A and D) confirmed the gating required 
for the successive plots as they indicate where healthy cells reside. Strangely, 
A and D should be on a similar plane in the y axis to the rest of the plots. This 
                                                 





is to indicate positive labelling of neutrophils with the specific neutrophil 
antibody CD66b. The other sets of neutrophils show a higher concentration of 
CD66b labelling, which may be due to the length of time the different sets of 
cells were incubated with the antibody and would require further experiments 
to confirm this. 
Two sets of neutrophils were incubated with probe 55 (Figure 3.10, B and C) 
but not activated by the tripeptide, and hence the small values, 10.5% and 8.6%, 
were expected when comparing to the same conditions but in presence of the 
tripeptide as an activation agent (Figure 3.10, E and F). The wide spread of 
counts in the density plots of the activated sets would require further 
investigation but at this stage, the confirmation of increased labelling with 




HNE inhibitors with high water solubility are ideal to microdose in the lung 
(through a bronchoscope) to identify potential inflammatory sites, or to aid in 
rapid diagnosis of pulmonary diseases. Here, four optical probes were 
successfully synthesised and purified in moderate yields and validated on the 
green and red channels to confirm the presence of human neutrophil elastase. 
In addition to two different fluorophores, two different spacer groups between 
the oxo-β-lactam warhead and the fluorophore were also incorporated, 
allowing comparison of the reactivity of the probes. The aryl spacer was 
shown to have a higher affinity towards HNE over the alkyl spacer, in addition 
to having a lower affinity towards other serine proteases. There was no 
noticeable difference in their cytotoxicity, the optical probes with an aryl space 





probes 55 and 56. However the optical probes with an alkyl spacer 
demonstrated a longer half-life in PBS over 51 and 52.   
The optical probes were determined to have IC50 values between 25 and 60 nM, 
and their half-lives in PBS were at least 22 hours but lacked stability in DMEM 
media. The two Cy5 probes 52 and 56 were confirmed to have formed a 
covalent bond with HNE via gel electrophoresis, and flow cytometry was used 
to confirm probe 55 was labelling activated neutrophils. The probes were used 






Chapter 4 GSK drug-based elastase 
targeting optical probe 
4.1 Introduction 
 
To develop a useful always-on optical probe, a highly specific targeting moiety 
is required, which is selective for human neutrophil elastase (HNE) over other 
analogous serine proteases. For the probe to be applicable in vivo, 
biocompatibility is essential, in addition to excellent clearance by the metabolic 
system. Given HNE has been correlated with a wide range of chronic 
pulmonary diseases, pharmaceutical companies have used the enzyme as a 
potential treatment target. To generate a highly specific optical probe, an HNE 
targeting drug can be incorporated into the structure. This is advantageous as 
a vast number of initial screening has been done before, including the 
specificity and affinity studies for HNE over other related serine proteases.  
HNE inhibitors slow down the enzyme activity which reduces the degradation 
of the pulmonary tissue. To date, there is only one commercially available 
treatment for the inhibition of HNE activity, Sivelestat, 57 (Figure 4.1). The 
drug has been surrounded by vague and contradictory results regarding it as 
a treatment option for ALI. Sivelestat was approved for two clinical trials: one 
in Japan and the STRIVE study, a Europe wide study. The Japanese study gave 
a positive outcome of reducing the number of days a patient requires 
ventilation, whereas the STRIVE study was terminated early due to the 
mortality rate of both the placebo and drug group being equivalent. As a 
result, 57 is only available as a treatment in South Korea and Japan.109–111  
In addition to the controversy regarding Sivelestat, the mechanism of the drug 
is slowly reversible, making it unsuitable for manipulation to become an 






Figure 4.1. Structure of the HNE inhibitor Sivelestat (ONO-5046), 57, Ki = 
200 nM, IC50 = 44 µM.112  
 
HNE has been a popular drug target for chronic obstructive pulmonary 
disease (COPD) after several years of research found a link between the two.54–
56 A library of second-generation inhibitors for the enzyme were developed by 
GSK; suicidal small molecules designed to bind irreversibly in the active site. 
The inhibitors all comprised the same motif: a ‘warhead’ attached to a long 
hydrophilic tail that interacts with the tunnel of the active site in the enzyme. 
The warhead consists of a pyrrolidine trans-lactam which covalently binds to 
the hydroxyl group of the serine residue in the active site (Ser203) (Figure 4.2).  
 
Figure 4.2. A) The HNE inhibitor GW311616A, 58;113 B) crystal structure of 
58 complexed in the active site of porcine pancreatic elastase. The structure 
has dotted lines to represent bonding between the substrate and enzyme, at 






The library of inhibitors was published in 2002 and, 58 was demonstrated to 
be highly potent to HNE, and selective over other serine proteases.41 The IC50 
of 58 towards HNE was 22 nM compared to other serine proteases such as 
chymotrypsin (3 µM) and trypsin and cathepsin G (above 100 µM). The 
combination of selectivity towards HNE and the versatility of altering the ‘tail’ 
with different functional groups made it a suitable candidate as the targeting 
moiety for the optical probe.  
 
4.2 Aims of chapter 4 
 
HNE has long been a drug target due to its overexpression being symptomatic 
of several diseases including COPD and cystic fibrosis. The GSK inhibitor 58 
has proven to be specific towards HNE over other familial serine proteases, as 
well as compatible in vivo, due to rigorous testing required for 
pharmaceuticals. Due to the advantages of this inhibitor, the aim of this 
chapter was to synthesise the compound but include a slight modification to 
allow for the addition of a fluorophore. After formation of the modified 
inhibitor, a dye was to be conjugated to form a highly specific far-red probe. 
The probe was to undergo cursory biological studies including the affinity 
towards HNE as well as imaging the probe in vitro.  
 
4.3 Synthesis of elastase targeting warhead 
 
The GSK inhibitor 58 can be disconnected to form two separate moieties: the 
warhead and the tail (Scheme 4.1). The tail can be easily modified to 
incorporate a fluorophore by substituting the piperidine for a piperazine, 







Scheme 4.1. Disconnection of GSK inhibitor 58, to the warhead 59 and the 
hydrophilic tail 60. 
 
The synthesis of inhibitor 58 was developed by GSK, by starting with L-
methionine (Scheme 4.2). The first reaction involved the Boc protection of the 
α-amino group with Boc anhydride under basic conditions. 
 
Scheme 4.2. First two steps towards the synthesis of 59. Reaction conditions: 
i) 1.25 M NaOH, Boc2O, dioxane, 0 °C to rt, 3.5 h; ii) pyridine, NH4HCO3, 
Boc2O, DMF, 18 h, 50% over i) & ii); iii) n-BuLi, benzyl chloroformate, THF, -
70 °C, 1.5 h, 96%. 
 
The subsequent step involved amidation of the carboxylic acid. Firstly, the free 
carboxylic acid was activated to give a mixed anhydride that then reacted with 
ammonia to generate the carboxamide 62 (Scheme 4.3). The generation of the 
by-product CO2 was observed by effervescence throughout the reaction. The 
presence of product 62 was confirmed by the presence of the characteristic two 






Scheme 4.3. Proposed mechanism for the amidation of Boc protected L-
methionine to form 62. 
 
An orthogonal protecting group was introduced onto the newly formed amide 
moiety in the form of a benzyl carbamate to generate 63. This was achieved by 
deprotonation of 62 by n-BuLi which enabled nucleophilic attack on benzyl 
chloroformate with subsequent elimination of the chloride yielding in the 
desired carbamate. As the reaction required low temperatures (-70 °C) and 
was highly water sensitive, scale up proved challenging but several small-
scale reactions gave 63 largely in quantitative yield.  
 
Scheme 4.4. Synthesis of lactam 65. Reaction conditions: i) MeI, acetone, rt, 
3 d, dark, 78%; ii) Amberlite IRA-410 (hydroxide form), MeCN, 4 Å molecular 
sieves, 45 °C, 4.5 h, 42%. 
 
To generate lactam 65, the protected methionine amide 63 was methylated to 
generate the sulfonium ion as a leaving group (Scheme 4.4). Subsequent 
reaction of 64 generated dimethyl sulfide, upon nucleophilic attack by the 
amide anion on the gamma carbon. The purification of 64 was difficult to 





should occur during the reaction and the product recrystallized with diethyl 
ether, but this was not reliable. Due to the difficulty in obtaining pure product, 
the crude 64 was carried into to the following step.  
The cyclisation step to generate the pyrrolidone 65, involved using a resin, 
Amberlite IRA-410 in its strongly basic form (Scheme 4.5). The Amberlite resin 
was functionalised with 10 M NaOH before washing with H2O, MeCN and 
drying with diethyl ether. Following the reaction, the mixture was filtered 
through a plug of silica to remove the physical contaminants as well as the 
positively charged 64 and the crude product crystallised to give 65 in an 
average yield of 47% (Scheme 4.5). 
 
Scheme 4.5. Functionalisation of Amberlite IRA 410 (A) and proposed 




The reaction mechanism was postulated to be a deprotonation of the amide by 
the functionalised resin to form an iminolate, allowing the double bond 
present on the nitrogen to attack the gamma carbon, releasing dimethyl 
sulphide. The positive charge on the sulfur makes this reaction possible. The 
positively charged starting material to the relatively hydrophobic product, 
makes the reaction easy to monitor by HPLC, as well as the distinctive odour 






Figure 4.3. HPLC traces showing the conversion of 64 (blue trace, tR = 0.73 
min) to 65 (red trace, tR = 4.82 min), using the wavelength 254 nm. 
 
Functionalisation of pyrrolidone 65 was carried out in preparation for the 
synthesis of the bicycle system in 58 (Figure 4.2). 
Scheme 4.6. Synthesis of 67 from 65. Reaction conditions: i) 4 M HCl, 
dioxane, 2.5 h; ii) N-methyl morpholine, methyl trifluoroacetate, DCM, MeOH, 
18 h, 51% over steps i & ii; iii) LiBH4, THF, -35 °C, 3.5 h; iv) EtOH, H2SO4, -20 
°C to rt, 3.5 h, crude 94% over steps iii & iv. 
 
Thus, the acid labile Boc protecting group was replaced with a 
trifluoroacetamide group by a two-step procedure: deprotection of the Boc 
group using HCl in dioxane, followed by reaction with methyl trifluoroacetate 
under basic conditions leading to the trifluoroacetamide 66 in moderate yield 
(51%) (Scheme 4.6). The trifluoroacetamide protecting group enables the 







Scheme 4.7. Proposed mechanism for the formation of 67 from 66. 
 
Reductive etherification of 66 was achieved by reduction of the carbonyl with 
lithium borohydride and etherification with ethanol under strongly acidic 
conditions (Scheme 4.8).  
 
Scheme 4.8. Reaction scheme for the alkylation of 67. Reaction conditions: i) 
BF3·OEt2, DCM, -20 °C to rt, 1.5 h, carried forward without purification. 
 
However, the following step involved the addition of another compound with 
a stereocentre, so separation of the two diastereomers was unnecessary. The 
synthesis of ketene acetal 68 was required before the reaction could be 






Scheme 4.9. A) Proposed mechanism of synthesis for the generation of 
ketene acetal 68; Reaction conditions: i) LiHMDS, THF/DMPU, 1 h, -78 °C, 
then TIPS-OTf, 2 h, 10%. B) two conformers of ethyl isovalerate that can be 
deprotonated to form either Z or E isomer; C) 1H NMR spectrum showing the 
ratio of Z and E isomers. 
 
The reaction involved the deprotonation of ethyl isovalerate by lithium 
bis(trimethylsilyl)amide (LiHMDS), resulting in the formation of an enolate 
(Scheme 4.9). The enolate was then reacted with triisopropylsilyl triflate, the 
triflate acting as a good leaving group. Due to the rotation present in ethyl 
isolvalerate, deprotonation of the alpha proton can generate two products: E 
and Z (Scheme 4.9). The ratio of the two compounds was determined to be 91:9 
Z/E through 1H NMR, by the CH2 of the ethyl group (Scheme 4.9, C). The 





material from the product. This proved challenging due to their similar 
properties and boiling points, and the acetal proved too labile to use other 
methods of purification. After the majority of the starting material was 
removed, the ketene acetal was then reacted with ethyl ether 67 in a large 
excess (5 equivalents) (Scheme 4.10).  
 
Scheme 4.10. Reaction of 67 to 69. Reaction conditions: i) BF3·OEt2, DCM, -
20 °C to rt, 1.5 h, carried forward without purification. 
  
The successive step was to alkylate ethyl ether 67 with the ketene acetal 68 in 
the presence of the Lewis acid boron trifluoride etherate (Scheme 4.11). The 
boron trifluoride complexes with the ethyl ether and the pyrrolidine forms an 
iminium species. This can then react with the ketene acetal, giving a mixture 
of isomers.  
 
Scheme 4.11. Proposed mechanism of the formation of 69. 
 
After generating 69, removal of the trifluoroamido protecting group was 
required before the second cyclisation step can occur (Scheme 4.12). This was 
achieved by refluxing compound 69 with K2CO3 in a mixture of ethanol and 
water for 4 hours, monitoring the presence of starting material by HPLC. The 
amine 70 was dried in vacuo to ensure there was no residual water present 






Scheme 4.12. Deprotection of the amine and lactamisation of 70 to generate 
71; Reaction conditions: i) K2CO3, EtOH/H2O, reflux, 4 h, carried forward 
without purification; ii) THF: TMEDA 1:1, tert-BuMgCl, 0 °C, 2 h, 30% of 71a, 
after purification. 
 
The lactamisation of compound 70 was achieved using a mixture of anhydrous 
TMEDA and THF to dissolve the amine, before the addition of tert-butyl 
magnesium chloride at 0 °C. The Grignard agent tBuMgCl was used as a base 
here, and there is the possibility that one of the protons from the amine group 
is removed, generating a strong nucleophile, enabling it to attack the ester. 
The requirement of the TMEDA was elucidated by MacDonald, with the 
hypothesis that it chelated the by-product MgO, which was found to react with 
the cyclised product 71a, lowering the yield and affecting the diastereomer 
ratio. Upon completion of the reaction, the diastereomers were separated by 
column chromatography, and the isolation of the intended isomer elucidated 






Figure 4.4. X-ray crystallography image of 71a, confirming the correct 
diastereomer was isolated. 
 
After successfully cyclising and purifying the bicyclic lactam, the next step was 
to sulfonate the amide (Scheme 4.13).  
 
Scheme 4.13. The generation of the sulphonamide 72. Reaction conditions: 
THF, LiHMDS, -78 °C, 1 h, then MeSO2Cl, 1 h, 50%. 
 
This reaction was achieved by deprotonation of the amide using LiHMDS 
under anhydrous conditions and reacting it with methanesulfonyl chloride, 
whereby the sulfonyl group is attacked by the deprotonated amide with 
subsequent elimination of the chloride. The reaction was difficult to force to 
completion but purified by flash chromatography, with the remaining starting 
material recovered and reused. 
The final step before conjugation of the warhead to the hydrophilic tail 
involved removal of the remaining protecting group, the carboxybenzyl group 





presence of the catalyst palladium hydroxide on carbon. The reaction required 
2 hours for a quantitative conversion and required no further purification.  
 
 
Scheme 4.14. Removal of the Cbz protecting group to generate amine 59. 
Reaction conditions: i) Pd(OH)2/C, H2, 3 h, quant. 
 
4.4 Preparation of the hydrophilic component of 
GSK inhibitor 
 
In addition to the warhead which directly binds to the enzyme active site, the 
GSK inhibitor also comprises of a ‘tail’: a longer hydrophilic moiety which has 
secondary interactions with the tunnel leading to the active site. The original 
design required a slight modification to contain a suitable functional group for 
conjugation to the dye (Figure 4.6). 
 
Figure 4.5. The structure modification of the original tail 60 to 73, to 
incorporate an amine group suitable for the addition of a fluorophore. 
 
The addition of the piperazine rather than a piperidine to 73 would give rise 
to a secondary amine that could react with a carboxyl functionalised 
fluorophore. The synthetic pathway to 73 was like that of 60, except that it 
required an additional protecting group on the secondary amine and an 






Scheme 4.15. Synthesis of the piperazine modified tail in solution. Reaction 
conditions: i) N-Boc piperazine, K2CO3, MeCN 63%; ii) 4 M HCl/dioxane & 
EtOH, reflux, 3 h, quant. 
 
The ester ethyl-4-bromocrotonate underwent an SN2 reaction with mono N-
Boc protected piperazine to form the intermediate 75 in a 63% yield. The Boc 
group was selectively cleaved through acidic hydrolysis in the solvent system 
ethanol and dioxane. The subsequent step was to react 76 with a fluorophore 
and its activated carboxylic acid group. Although the synthetic route was 
straightforward, the handling of 76 proved challenging. Several reactions were 
attempted to complete the final conjugation to the dye, but all were met with 
little to no reaction (Table 4.1). The activating agents were altered, in addition 
to the quantity of the base, and the dye as it was assumed the accessibility of 
the carboxyl group interfered with the reaction. All the alterations gave no 
noticeable effect to increasing reaction yield.  
Table 4.1. Reaction conditions investigated for the addition of a fluorophore to 
76. * = Visible on HPLC chromatogram. 
Reaction conditions Fluorophore Product 
DIPEA 25 No  
TEA BODIPY-NHS No  
HSPyU, DIPEA Cy5 27 <5%* 
Oxyma, DIC Cy5 27 No 






To circumvent the use of 76, the problem was approached in a different 
manner (Scheme 4.16). The need for a terminal carboxylic acid meant it was 
possible to use solid phase synthesis as a method of solving the handling 
issues associated with the hydrophilicity of the compound. An additional 
benefit of using this technique would be lack of protecting groups, as the Boc 
group on the piperazine would no longer be necessary. The use of solid phase 
synthesis is also advantageous for modifying the tail structure, as it would be 
possible to modify the reaction by simply adding a different fluorophore or an 
extended spacer. 
          
              
Scheme 4.16. The solid-phase approach to synthesis of tail 79. Reaction 
conditions: i) Ca(OH)2, EtOH/H2O (1:1), 18 h, 35%; ii) 2-chlorotrityl 
polystyrene resin, SOCl2, DCM, 1 h, then 77 (625 mM), DMF, 2 h; iii) 
piperazine, DMF, DIPEA, 2 h, carried forward without purification. CT = 2-
chlorotrityl polystyrene resin. 
 
To generate the tail, the carboxylic acid of 74 was first unmasked using calcium 
hydroxide in a mixture of water and ethanol (Scheme 4.14). This was a poor 
yielding reaction, but it produced enough material for the subsequent 
reaction. The polystyrene 2-chlorotrityl resin was first activated using thionyl 
chloride under anhydrous conditions. The acid was dissolved in the minimum 
amount of DMF required and added to the resin at a concentration of 625 mM, 
to give as a high a loading onto the resin as possible. The resin then was 
swelled with DCM and a solution of piperazine in DMF was added. The 





Kaiser test as it had to highlight the presence of a secondary amine on the resin, 
instead of a primary.114 Confirmation of reaction was achieved by a test 
cleavage of the compound from the resin and HPLC analysis (Figure. 4.6). 
 
Figure 4.6. HPLC traces monitoring the formation of the hydrophilic tail on 
resin. Bottom trace is a test cleave of the bromo crotonate 78 (blue, tR = 2.98 
min) and top chromatogram is the piperazine modified crotonate, 79 (red, tR 
= 1.51 min). All traces were analysed in the ELSD channel. 
 
4.4.1 Addition of the fluorophore to the tail 
 
 
Scheme 4.17. Solid-phase synthesis of the tail 80. Reaction conditions: i) 
HSPyU, DIPEA, DMF, 3 h; ii) 79, DIPEA, 18 h, 8% after purification (assuming 
>90% loading onto resin). Cleavage from the linker was achieved with 20% 






To complete the synthesis of the tail, Cy5 dye 27 was activated using HSPyU 
and DIPEA, with active ester formation confirmed through HPLC analysis 
(Scheme 4.17). The activation of the carboxyl group was quantitative, but 
subsequent conjugation of the activated dye to the piperazine was poor 
yielding, regardless of the ratio/concentration of starting materials used. 
The test cleavages showed both starting material and product, but longer 
reaction times did not lead to full conversion. The crude product was removed 
from the resin using the cleavage cocktail of 20% HFIP in DCM. Product 80 
was then isolated using reverse phase semi-preparative HPLC (Figure 4.7). 
 
 
Figure 4.7. HPLC traces monitoring the activation of the carboxylic acid on 
Cy5 dye 27 (blue trace, tR = 3.71 min) to an active ester (red trace, tR = 4.01 
min), and after the reaction with the piperazinyl moiety to form the amide 80 
(green trace, tR = 3.16 min). Data was normalised to 1, and the reaction 






4.4.2 Generation of the far-red elastase specific optical probe 
 
Scheme 4.18. The final reaction for the generation of optical probe 81. 
Reaction conditions: i) EDC.HCl, HOBt, MeCN, DMF, 18 h, 10% after 
purification. 
 
Conjugation of the tail to the warhead was achieved using EDC (N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide) and HOBt (hydroxy 
benzotriazole) as coupling reagents (Scheme 4.18). Thus, activation of the 
carboxylic acid via an O-acylurea intermediate was followed by subsequent 
attack by HOBt to generate the HOBt ester which reacted with the amine to 







Scheme 4.19. Proposed mechanism of carboxylic acid activation using HOBt 
and EDC.HCl, before amidation. 
 
The hydrophilicity of the final compound meant it required purification using 
reverse phase semi-preparative HPLC, with probe formation confirmed 
through mass spectrometry. The overall yield of the reaction was poor, with a 
final mass of 1.2 mg and 10% yield, however this was sufficient for further 
biological evaluation. Probe 81 was analysed to determine its excitation and 







Figure 4.9. Absorption (blue, λEx = 648 nm) and emission (red, λEm = 666 
nm) spectra of 81 in PBS, normalised to 1 (emission spectrum observed after 
excitation at 630 nm). 
 
4.5 Biological evaluation of far-red optical probe 
81 
 
The optical probe 81, after purification, was then investigated for its suitability 
in a biological setting. This involved determining the toxicity towards 
mammalian erythrocytes, the Ki when incubated with HNE and in vitro live 
cell imaging of neutrophils. 
 
4.5.1 Ki determination for the optical probes 
The inhibitor 58 was investigated by McDonald and was determined to have 
a Ki of 0.31 nM.113 The far-red probe 81 was investigated in a similar manner 
to determine how the Ki had changed through the addition of the dye. This 
was achieved by using the substrate for the enzyme MeOSuc-Ala-Ala-Pro-Val-
pNA. A serial dilution of the probe from 500 nM to 7.8 nM and then added to 





each inhibitor concentration, the progress curve was transformed into kobs and 
plotted against the concentration (Figure 4.10).   
 
Figure 4.10. Graph of kobs against concentration of optical probe 81, for the 
determination of Ki (extrapolated as the Km of the line of best fit), n=3. 
 
The Ki, the Km of the line of best fit, which was found to be 37 nM, a hundred-
fold higher than that of its parent molecule 58, but it had still retained 
efficiency. The error bars present in Figure 4.10 highlights the variety in results 
kobs varied throughout the concentrations, and so more experiments should be 
done to achieve a more reliable value.  
4.5.2 Toxicity of optical probes 
With the aim of using the optical probe in vivo, toxicity of the compound had 
to be taken into consideration. Probe 81 was incubated with human 
erythrocytes, as a haemolysis assay gave a more realistic idea of toxicity in the 
area of interest over other, more frequently used assays. The assay involved 
an hour incubation of the probes with isolated erythrocytes at 37 °C. The assay 





of the supernatant was analysed to identify how much porphyrin was released 
through lysis of the cells, in comparison to a calibration curve.  
 
Figure 4.11. Haemolysis assay of the optical probe 81 at two different 
concentrations, with the data compared to control haemolysis, n=3. 
 
The data interpretation highlights that even at ten-fold concentration required 
for imaging has an average toxicity of 1.2%, and a toxicity of 0.5% at a ten-fold 
less concentration required for confocal imaging. This demonstrated minimal 
toxicity of 81, particularly at the concentrations required for imaging, which is 
beneficial for the end use of in vivo imaging.  
 
4.5.3 Scanning confocal microscopy of optical probe 81  
Due to the nature of the compound, the imaging agent had to confirm that it 
was possible to use it as an optical imaging agent. Neutrophils were isolated 
from whole human blood and activated using a calcium ionophore (1 µM) for 
two minutes before adding probe 81 and Neutrophil Activated Probe, or NAP 
(Figure 1.19, 20). NAP is a peptide based optical probe that was developed 
previously in the research group, which is a tri-branched peptide containing 





peptide chain, releasing the fluorescein from the self-quenching mechanism. 
Figure 4.12 shows the overlap of both HNE targeting probes, confirming 
qualitatively that 81 can label HNE expression from neutrophils. 
 
 
Figure 4.12. Live confocal imaging of human neutrophils activated by calcium 
ionophore (1 µM, 5 min) with the optical probe 81 and HNE specific in-house 
probe, NAP 20 (green). Image (A) was NAP (2 µM, 10 min incubation), (B) 
was stained with 81 (2 µM, 10 min incubation), and (C) is a merged overlay of 




HNE inhibitors with high water solubility are ideal to microdose in the lung 
(through a bronchoscope) to identify potential inflammatory sites, or to aid in 
rapid diagnosis of pulmonary diseases. The GSK drug for COPD, 58, has 
proven to be a highly designed compound for the active site of the enzyme 
HNE. This has been successfully manipulated to include a secondary amine 
and to it, a far-red dye has been added. This created a highly specific, always-
on, optical probe to detect HNE at physiological levels.  
The Ki was determined to be only slightly affected by the addition of the with 
a small reduction in efficacy, as 58 had a Ki of 0.31 nM and the Ki of the far-
                                                 





red optical probe 81 was determined to be 37 nM. The far-red probe was 
shown to be non-toxic towards erythrocytes, as well as neutrophils. It was 






Chapter 5 Experimental 
 
5.1 General remarks 
 
Chemicals were purchased from Sigma Aldrich, Honeywell, Merck, Acros, 
VWR International, TCI Chemicals, or Fischer Scientific and used without 
further purification. All experiments that required an oxygen free 
environment were carried out using Schlenk techniques unless otherwise 
stated. Solvent removal was carried out at a reduced pressure on a Büchi 
rotary evaporator, or overnight in a Heraeus vacuum oven at 40 °C. 
All melting points were obtained using a SMP10 melting point apparatus from 
Bibby Scientific Ltd. Infrared spectra were obtained using a Bruker FT-IR 
Tensor 27. All 1H and 13C NMR spectra reported were carried out at 297 K 
(unless otherwise stated) in deuterated solvents (D2O, CDCl3, DMSO or 
MeOD) and recorded using a Bruker AVA 500 or a Bruker AVA 600 (500 and 
126 MHz; 600 and 150 MHz), and all coupling constants are reported in Hz. 
The 1H spectra are characterised as singlet (s), broad singlet (br s), doublet (d), 
doublet of doublet (dd), triplet (t), quartet (q) or multiplet (m). Analytical TLC 
was carried out using Merck aluminium backed silica gel plates (F254), reverse 
phase TLC using Macherey Nagel RP-18 ALUGRAM (UV254) sheets, both 
visualised using a Mineralight UV lamp with illumination at wavelengths of 
254 and 365 nm. Chromatography purification was carried out using silica gel 
(60–120 mesh). Reverse phase chromatography was on a Biotage Isolera using 
SNAP Ultra C18 columns (12 g, 30 g). Microwave assisted reactions were 






Low resolution mass spectrometry data was obtained using an Agilent 6130 
Quadrupole LC-MS system, and high-resolution mass spectrometry 
determined on a Bruker 3.0T Apex Spectrometer.  
Reverse-phase preparative HPLC was achieved using an Agilent 1260 Series 
ChemStation and on an Eclipse XDB C-18 column (5 µm, 9.4 × 250 mm), or 
Kinetex 5 µm XB-C18 100A (150 × 21.2 mm). The solvents used were MeCN + 
0.1% FA and H2O + 0.1% formic acid, initially 5% MeCN and increased by 1% 
per minute for 20 mins. The procedure had a flow rate of 2 mL/min and UV 
detection at 254 nm. Analytical HPLC was achieved using an Agilent 1100 
Series ChemStation and on an Eclipse C-18 column (5 µm, 9.4 × 150 mm). 
Solvents used for Method A were MeCN + 0.1% formic acid and H2O + 0.1% 
formic acid, with an initial gradient of 5% MeCN, increasing by 15% per 
minute for 6 min, maintained at 95% MeCN for 3 min. The procedure had a 
flow rate of 1 mL/min and the traces stated are from an ELSD unless otherwise 
stated. Absorbance and fluorescence spectra were obtained using either a 
Fluoromax spectrophotometer, or a Synergy Biotek plate reader and analysed 
using the Gen5 software.  
Enzymatic assays were carried out on a Synergy Biotek plate reader. Gel 
electrophoresis was carried out on a buffered gel system using a Bio-Rad 
PowerPac 300 power supply and analysed on a Bio-Rad Gel Doc XR+ system. 
Flow cytometry was achieved using a 5L LSR Fortessa and the data analysed 
using FlowJo software (version 7.2.4). Live cell imaging used a Leica SP8 
confocal microscope or an Andor spinning disc microscope, using the laser 
lines: 405 nm, 488 nm and 630 nm.  
5.2 Synthesis of molecules 
 






5(6)-Carboxyfluorescein (15.0 g, 40 mmol) was added to acetic anhydride (180 
mL, 1.9 mol) and pyridine (18 mL) and was heated to reflux (120 °C) for 1 h. 
The conversion was confirmed by HPLC analysis (tR = 4.85 min, ELSD). The 
solvent was removed in vacuo and the crude product was redissolved in EtOAc 
(150 mL) before being washed with KHSO4 (1 M, 2 × 100 mL) and brine (100 
mL). The organic layer was collected and dried with MgSO4 and the solvent 
removed in vacuo, with the crude product 5(6)-carboxyfluorescein diacetate 
used without further purification in the subsequent reaction.  
5(6)-Carboxyfluorescein diacetate (40 mmol) and N-hydroxsuccinimide (5.50 
g, 47.9 mmol) was added to DCM (100 mL) and left to stir until dissolved. To 
the solution DIC (7.4 mL, 47.9 mmol) was slowly added and the reaction was 
left to stir for 0.5 h. After confirmation of reaction by TLC, it was washed with 
H2O (100 mL), brine (100 mL) and dried using MgSO4. DCM was removed in 
vacuo. The crude product was purified using a silica column with isocratic 
solvent system of EtOAc/toluene (2:8) to afford 5-carboxyfluorescein diacetate 
N-hydroxysuccinimde ester 25 (36%) and 6-carboxyfluorescein diacetate N-
hydroxysuccinimde ester 26 (24%) as colourless solids.87  
 
5-Carboxyfluorescein diacetate N-hydroxysuccinimide ester (25) 
Colourless solid, yield: 8.67 g (36%); 1H NMR δ (500 MHz, CDCl3) 8.40 (dd, 
1H, J = 8.1, 1.3 Hz, ArH), 8.18 (dd, 1H, J = 8.0, 0.6 Hz, ArH), 7.93 (dd, 1H, J = 
1.3, 0.6 Hz, ArH), 7.14 (d, 2H, J = 2.3 Hz, ArH), 6.86 (dd, 2H, J = 2.3, 8.7 Hz, 
ArH), 6.79 (d, 2H, J = 8.7 Hz, ArH), 2.88 (br s, 4H, 2 × CH2), 2.31 (s, 6H, 2 × 
CH3); 13C NMR δ (126 MHz, CDCl3) 168.78 (C=O × 2), 168.77 (C=O × 2), 167.54 





131.74 (C), 131.47 (C), 128.98 (2 × CH), 126.46 (CH), 126.03 (CH), 118.23 (2 × 
CH), 115.37 (2 × C), 110.81 (2 × CH), 82.45 (C), 25.77 (2 × CH2), 21.27 (2 × CH3); 
Rf: 0.53 (EtOAc:Toluene 50:50); HPLC (Method 1/ACN) tR = 5.22 min, purity 
100% (ELSD); ESI-MS (MeCN): m/z = 465.1 [M+Na]+. Data in accordance with 
the literature.87 
 
6-Carboxyfluorescein diacetate N-hydroxysuccinimide ester (26) 
Colourless solid, yield: 4.67 g (24%); 1H NMR δ (500 MHz, CDCl3) 8.81 (dd, 
1H, J = 1.5, 0.7 Hz, ArH), 8.41 (dd, 1H, J = 8.1, 1.6 Hz, ArH), 7.36 (dd, 1H, J = 
8.1, 0.7 Hz, ArH), 7.13 (d, 2H, J = 2.2 Hz, ArH), 6.85 (dd, 2H, J = 8.7, 2.3 Hz, 
ArH), 6.80 (d, 2H, J = 8.7 Hz, ArH), 2.93 (br s, 4H, 2 × CH2), 2.31 (s, 6H, 2 × 
CH3); 13C NMR δ (126 MHz, CDCl3) 168.93 (C=O × 2), 168.84 (C=O × 2), 167.35 
(C=O), 160.60 (C=O), 158.24 (C), 152.53 (2 × C), 151.58 (2 × C), 136.98 (CH), 
128.95 (2 × CH), 128.12 (CH), 127.74 (C), 127.25 (C), 125.18 (CH), 118.20 (2 × 
CH), 115.31 (2 × C), 110.81 (2 × CH), 82.15 (C), 25.81 (2 × CH2), 21.23 (2 × CH3); 
HPLC (Method 1/ACN) tR = 5.38 min, purity 100% (ELSD); Rf: 0.37 
(EtOAc:Toluene 50:50); ESI-MS (MeCN): m/z = 465.3 [M+Na]+. This is in 
accordance with the literature.87 
 
2,3-Trimethyl-3H-indole-5-potassium sulfonate (28) 
4-Hydrazinobenzenesulfonic acid (6.00 g, 0.032 mol) and 3-methyl-2-butanone 
(10.2 mL, 0.096 mol) were dissolved in acetic acid (30 mL) and the stirred 





residue was then dissolved in methanol (30 mL) and stirred in a saturated 
solution of KOH in 2-propanol (200 mL). The potassium salt was collected 
from the resulting solution by filtration. 
 
Pale orange solid, yield: 7.761 g, (78%). IR vmax / cm-1: 1574 (C=C str), 1265 (C-
Nar str), 1193 (S=O str); 1H NMR δ (500 MHz, MeOD) 8.12 (1H, d, J = 1.3 Hz, 
ArH), 8.04 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.89 (1H, d, J = 8.4 Hz, ArH), 4.11 (3H, 
s,  CH3), 1.65 (6H, s, 2 × CH3); 13C NMR δ (126 MHz, MeOD) 199.47 (C), 148.47 
(C), 144.42 (C), 143.11 (C), 128.32 (CH), 122.08 (CH), 116.16 (CH), 56.00 (C), 
35.47 (CH3), 22.33 (2 × CH3); ESI-MS (MeCN): m/z = 278.1 [M-H]+. Data in 
accordance with the literature.98 
 
1-Ethyl-2,3,3-trimethyl-5-sulfo-3H-indolinium (29) 
Iodoethane (12 mL, 0.15 mol) and the sulfonated indole 28 (2.00 g, 0.18 mol) 
were added together, flushed with N2 and were left to reflux for 48 h with the 
reaction monitored by HPLC. Upon completion, the reaction precipitate was 
filtered, washed with Et2O (2 × 150 mL), and dried in a vacuum oven overnight 
to give the product as a purple solid (2.51 g, 98%).  
 
Pale solid, yield: 2.51 g (98%). IR vmax / cm-1: 1224 (C-Nar str), 1185 (S=O str); 1H 
NMR δ (500 MHz, MeOD) 8.17 (1H, d, J = 1.2 Hz, ArH), 8.09 (1H, dd, J = 8.4, 
1.6 Hz, ArH), 7.98 (1H, d, J = 8.4 Hz, ArH), 4.62 (2H, q, J = 8.4 Hz, CH2), 3.97 
(1H, m, CH), 1.67 (6H, s, 2 × CH3), 1.62 (3H, t, J = 7.4 Hz, CH3); 1.19 (3H, s, CH3); 
13C NMR δ (126 MHz, MeOD) 199.32 (C), 148.58 (C), 143.58 (C), 143.11 (C), 





(2 × CH3), 13.10 (CH3); ESI-MS (MeCN): m/z = 306.1 [M-H]-. Data in 
accordance with the literature.99  
 
1-(5-Carboxypentyl)-2,3,3-trimethyl-5-sulfo-3H-indolium (30) 
6-Bromohexanoic acid (1.0 g, 5.12 mmol) and the sulfonated indole 28 (1.2 g, 5 
mmol) were added together and diluted in a mixture of MeCN and DMF (9:1, 
20 mL) and heated in the microwave for 3 h to 120 °C, with the reaction 
monitored by HPLC. Upon completion, the reaction precipitate was filtered, 
washed with Et2O (2 × 150 mL), and dried in a vacuum oven overnight to 
produce the product as a dark red solid (1.06 g, 60%).  
 
Dark red solid, yield: 1.06 g, (60%). IR vmax / cm-1: 2924 (O-H br, str), 1710 (C=O 
str), 1592 (C=C), 1161 (S=O str); 1H NMR δ (500 MHz, MeOD) 8.17 (d, J = 1.3 
Hz, 1H, ArH), 8.10 (1H, dd, J = 8.4, 1.6 Hz, ArH), 7.96 (1H, d, J = 8.5 Hz, ArH), 
4.59 (2H, m, CH2), 2.38 (2H, t, J = 7.2 Hz, CH2), 2.02 (2H, m, 2H, CH2), 1.74 (2H, 
m, CH2), 1.67 (6H, s, 2 × CH3), 1.58 (2H, m, CH2), 1.54 (3H, s, CH3); 13C NMR δ 
(126 MHz, MeOD) 198.31(C), 175.70 (C), 147.23 (C), 142.07 (C), 127.12 (CH), 
120.98 (CH), 115.17 (CH), 54.82 (C), 47.88 (CH2), 32.94 (CH2), 27.05 (CH2), 25.64 
(CH2), 23.98 (CH2), 21.38 (CH3), 21.24 (2 × CH3); ESI-MS (MeCN): m/z = 354.1 








29 (0.50 g, 1.87 mmol) and malonaldehyde dianilide hydrochloride (0.546 g, 
2.11 mmol) were added together, diluted with a mixture of AcOH and acetic 
anhydride (1:1, 20 mL) and left to reflux for 4 h. The solvent was removed in 
vacuo, and the crude product was washed repeatedly with a mixture of 
Et2O/EtOAc (1:1, 250 mL) until the filtrate turned colourless. The crude 
product was collected and dried in a vacuum oven at 40 °C for 18 h. 
The dark brown product (0.491 g, 1.2 mmol) was added to 30 (0.416 g, 1.18 
mmol) and a mixture of AcOH and acetic anhydride added (3:1, 8 mL). After 
the reactants had dissolved, NaOAc (0.377 g, 4.6 mmol) was added and the 
reaction was left to reflux for 4 h, with the reaction monitored by HPLC. The 
crude reaction mixture was added slowly to stirring Et2O (150 mL), the dark 
blue precipitate collected by filtration and washed several times with Et2O (3 
x 100 mL). The crude product was dried and purified using reverse phase 
chromatography to yield 27 as a dark blue solid (0.49 g, 26%). 
 
Dark blue solid, yield: 0.485 g, (26%); IR vmax / cm-1: 2928 (O-H, str), 1708 (C=O, 
str), 1326 (C-Nar, str), 1216 (S=O, str); 1H NMR δ (500 MHz, D2O) 8.05 (1H, dd, 
J = 12.9, 6.7 Hz, CHar), 8.03 (1H, dd, J = 13.1, 6.6 Hz, CHar), 7.88 (1H, d, J = 1.7 
Hz, CHar), 7.86 (1H, d, J = 1.6 Hz, CHar), 7.84 (1H, dd, J = 8.4, 1.8 Hz, CHar), 
7.81 (1H, dd, J = 8.7, 2.0 Hz, CHar), 7.36 (1H, d, J = 8.4 Hz, CHar), 7.32 (1H, d, J 
= 8.4 Hz, CHar), 6.55 (1H, t, J = 12.5 Hz, CHar), 6.28 (1H, d, J = 14.1 Hz, CHar), 
6.22 (1H, d, J = 13.6 Hz, CHar), 4.11 (2H, q, J = 7.5 Hz, NCH2), 4.06 (2H, t, J = 7.1 





(6H, s, 2 × CH3), 1.67 (6H, s, 2 × CH3), 1.67-1.63 (2H, m, CH2), 1.46-1.40 (2H, m, 
CH2), 1.36 (3H, t, J = 7.4 Hz, CH2CH3); 13C NMR δ (126 MHz, MeOD) 177.21 
(C=O), 175.32 (C), 175.09 (C), 156.39 (CH), 156.21 (CH), 144.92 (C), 144.42 (C), 
143.51 (C), 143.39 (C), 142.75 (C), 142.59 (C), 128.09 (CH), 128.06 (CH), 127.65 
(CH), 121.42 (CH), 121.37 (CH), 111.62 (CH), 111.40 (CH), 105.17 (CH), 104.95 
(CH), 50.65 (C), 50.59 (C), 45.07 (CH2), 40.25 (CH2), 34.58 (CH2),  28.09 (CH2), 
27.83 (2 × CH3), 27.72 (2 × CH3), 27.30 (CH2), 25.66 (CH2), 12.50 (CH3); HPLC 
(Method 1/MeCN) tR = 3.67 min, purity 100% (ELSD); ESI-MS (MeCN): m/z = 
657.3 [M-H]-. Data in accordance with the literature.99  
 
2,3-Dimethyl-5-sulfo-3H-indole-3-butanesulfonic acid (38)98 
Sodium hydride (60% wt., 2.90 g, 72.8 mmol) was flushed with N2, before DMF 
(40 mL) was added, the mixture was cooled to 0 °C and left to stir for 10 min. 
Ethyl 2-methylacetoacetate (9.80 mL, 69.3 mmol) was added slowly, 
maintaining the temperature, and the mixture was left until effervescence had 
halted. The reaction mixture was then heated to 60 °C for 3 h. 1,4-butane 
sultone (7.2 mL, 69.3 mmol) was added slowly, keeping the temperature at 30 
°C. The mixture was then heated to 50 °C for 18 h. The solvent was removed 
in vacuo, the crude mixture re-dissolved in H2O (50 mL) and washed with Et2O 
(2 × 100 mL). The aqueous layer was isolated, transferred to a round bottom 
flask, and to it sodium hydroxide (3.56 g, 89.1 mmol) was added. The reaction 
was left at 90 °C for 18 h. The mixture was cooled to 30 °C and washed with 
hexane (2 × 30 mL). The aqueous phase was collected, cooled in an ice bath, 
and acidified to pH 2 using HCl. The solvent was removed in vacuo, and NaCl 
precipitated out. The residue was dissolved in MeOH (75 mL) and triturated 
for 10 min, before filtration to remove the salt. The methanolic solution was 
collected and the solvent was removed in vacuo to produce the crude product 





The yellow residue was dissolved in acetic acid (225 mL), flushed under N2 
atmosphere and to the mixture, 4-hydrazinobenzenesulfonic acid (13.0 g, 69.3 
mmol) was added. The reaction was heated to 105 °C for 12 h. The solvent was 
removed in vacuo to approx. 30 mL, and to the crude mixture isopropanol (150 
mL) was added, and left to stir at 60 °C for 2.5 h. The yellow precipitate was 
filtered off, washed with isopropanol (2 × 100 mL) and re-dissolved in a 
minimal amount of H2O (20 mL). 2 M aq. soln NaOH (approx. 10 mL) was 
added to the solution until the pH = 8. The solution was lyophilised to give 
the product as a yellow solid (10.3 g, 41% in 94% purity).  
 
Yellow solid, yield: 10.3 g, (41%). mp > 250 °C; IR vmax / cm-1: 1384 (S=O, str), 
1335 (C-Nar, str); 1H NMR δ (500 MHz, DMSO) 7.55 (1H, d, J = 1.5 Hz, ArH), 
7.52 (1H, dd, J = 1.7, 7.9 Hz, ArH), 7.31 (1H, d, J = 7.9 Hz, ArH), 2.20 (2H, m, 
CH2), 2.17 (3H, s, CH3), 1.85 (1H, m, C(H)H), 1.74 (1H, m, C(H)H), 1.41 (2H, m, 
CH2), 1.21 (3H, s, CH3), 0.67 (1H, m, C(H)H), 0.48 (1H, m, C(H)H); ESI-MS 
(MeOH): m/z = 360.1[M-H]-. Data in accordance with the literature.98 
 
2,3-Dimethyl-5-sulfo-1,3-bis(4-sulfobutyl)-3H-indolinium (39)98 
38 (0.50 g, 1.39 mmol) was loaded into a microvial and flushed with N2 and 
N,N-dimethylacetamide (12 mL) was added. The mixture was heated to 150 
°C, and after 10 min of trituration, 1,4-butane sultone (1.4 mL, 13.9 mmol) was 
added and the mixture was heated to 150 °C for 24 h. The reaction was cooled 
and filtered under N2. The solid was refluxed in EtOAc (10 mL) for 2 h and 
filtered again. The remaining solid was dried in a vacuum oven at 40 °C 





isopropanol was added and left to stir at 50 °C for 2 h before being filtered and 
washed thoroughly with isopropanol. The collected precipitate was left to dry 
in a vacuum oven overnight at 40 °C, to produce 39 (0.35 g, 51%) as a dark red 
solid. 
 
Dark red solid, yield: 0.35 g, (51%). mp 200 °C; IR vmax / cm-1: 1605 (C=C, str), 
1331 (S=O, str); 1H NMR δ (500 MHz, DMSO) 7.92 (1H, d, J = 8.7 Hz, ArH), 
7.91 (1H, s, ArH), 7.76 (1H, d, J = 8.7 Hz, ArH), 4.42 (2H, t, J = 7.6 Hz, CH2), 2.81 
(3H, s, CH3), 2.25 (2H, m, CH2), 2.18 (1H, m, C(H)H), 2.03 (1H, m, C(H)H), 1.87 
(2H, m, CH2), 1.70 (2H, m, CH2), 1.47 (3H, s, CH3), 1.37 (2H, m, CH2), 0.69 (1H, 
m, C(H)H), 0.49 (1H, m, C(H)H); 13C NMR δ (126 MHz, DMSO) 197.27 (C), 
149.46 (C), 141.56 (C), 139.87 (C), 126.55 (CH), 120.79 (CH), 115.05 (CH), 58.59 
(C), 50.33 (CH2), 50.09 (CH2), 47.52 (CH2), 35.96 (CH2), 26.19 (CH2), 24.74 (CH2), 
22.48 (CH2), 22.18 (CH2), 21.41 (CH3), 14.04 (CH3); ESI-MS (MeCN): m/z = 497.3 





Indole 30 (559 mg, 1.6 mmol) was added to malonaldehyde dianilide 
hydrochloride (563 mg, 2.2 mmol) and a mixture of acetic anhydride and acetic 
acid (1:1, 20 mL). The reaction was heated to reflux for 2 hours and monitored 





added to a mixture of Et2O and EtOAc (2:1, 150 mL). The precipitate formed 
was collected and washed with EtOAc (250 mL) and dried in a vacuum oven 
overnight. The intermediate was added to the sulfonate indole 39 (986 mg, 2.0 
mmol) in a mixture of acetic acid and acetic anhydride (1:2, 20 mL). Sodium 
acetate (1.07 g, 13 mmol) was added and the reaction mixture was heated to 
reflux until the reaction was complete. The crude mixture was cooled, added 
slowly to stirring Et2O (200 mL) and the product filtered off, dried and purified 




Dark blue solid, yield: 0.170 g, (12%); 1H NMR δ (500 MHz, MeOD) 8.28 (2H, 
d, J = 12.8 Hz, CHar), 7.85 (4H, m, 4 × CHar), 7.33 (2H, m, 2 × CHar), 6.69 (1H, t, 
J = 12.4 Hz CHar), 6.41 (1H, d, J = 13.5 Hz CHar), 6.34 (1H, d, J = 13.7 Hz CHar), 
4.12 (4H, m, 2 × NCH2), 2.91 (2H, br s, CH2), 2.64 (2H, br s, CH2), 2.49 (1H, m, 
CHH), 2.31 (2H, t, J = 7.3 Hz CH2COOH), 2.21 (1H, m, CHH), 1.94 (4H, br s, 2 
× CH2), 1.80 (2H, m, CH2), 1.73 (3H, s, CH3), 1.72 (3H, s, CH3), 1.71 (3H, s, CH3), 
1.65 (4H, m, 2 × CH2), 1.46 (2H, m, CH2), 1.02 (1H, br s, (CHH) 0.69 (1H, br s, 
(CHH); 13C NMR δ (126 MHz, MeOD) 177.15 (C=O), 175.62 (C), 175.54 (C), 
173.54 (C), 173.51 (C), 156.39 (CH), 155.64 (CH), 145.93 (C), 144.95 (C), 142.72 
(C), 140.75 (C), 128.28 (2 × CH), 128.06 (CH), 121.34 (CH), 121.30 (CH), 111.76 
(CH), 111.59 (CH), 105.93 (CH), 105.60 (CH), 54.94 (C), 52.27 (CH2), 51.80 





27.88 (CH3), 27.86 (CH3), 27.82 (CH3), 27.27 (CH2), 27.23 (CH2), 25.83 (CH2), 
25.64 (CH2), 24.94 (CH2), 23.54 (CH2); HPLC (Method 1/ACN) tR = 3.62 min, 
purity 100% (650 nm); ESI-MS (MeCN): m/z = 888.3 [M-H]-. Data in accordance 
with the literature.98 
 
3,3-Diethyl-1-(N-aminobenzylamino)-2,4-azetidinedione (49) 
Diethylmalonyl dichloride (0.19 mL, 1.12 mmol) was added to dry dioxane (5 
mL) and to the solution N-Boc-aminobenzylamine (0.25 g, 1.12 mmol) was 
added in anhydrous dioxane (5 mL) over an hour. To the mixture NEt3 (0.7 
mL) in dioxane was added slowly and then the reaction was left to stir at rt, 
for 18 h. The solid formed was filtered off, washed with hexane and the filtrate 
was dried in vacuo. The residue was purified using silica column 
chromatography (EtOAc:hexane, 0.2:9.8 → 1:1). This produced 49 (0.099 g, 
25%) as a colourless solid.  
 
Colourless solid, yield: 0.099 g, (25%); IR vmax / cm-1: 3330 (N-H, str), 1713 (C=O, 
str), 1456 (C=C); 1H NMR δ (500 MHz, CDCl3) 7.77 (2H, d, J = 8.1 Hz, 2 × CH), 
7.31 (2H, d, J = 8.3 Hz, 2 × CH), 4.96 (1H, br s, NH), 4.28 (2H, d, J = 2.3 Hz, 
NHCH2), 1.83 (4H, q, J = 7.5 Hz, 2 × CH2), 1.43 (9H, s, 3 × CH3), 1.04 (6H, t, J = 
7.5 Hz, 2 × CH3); 13C NMR δ (126 MHz, CDCl3) 172.20 (2 × C=O), 155.96 (C=O), 
137.86 (C), 132.95 (C), 128.28 (2 × CH), 119.46 (2 × CH), 79.73 (C), 72.21 (C), 
44.28 (CH2), 28.48 (3 × CH3), 24.03 (2 × CH2), 9.30 (2 × CH3); HPLC (Method 
1/MeCN) tR = 5.82 min, purity 100% (ELSD); HRMS (ESI+, MeCN) [M+H]+ 







49 (0.099 g, 0.29 mmol) was added to dioxane (3 mL) and to the solution 4M 
HCl in dioxane (0.7 mL) was added and the reaction was left to stir for 6 h. The 
reaction mixture was dried in vacuo to yield 50 as a white solid (0.071 g, 99%).  
 
Colourless solid, yield: 0.071 g, (99%); IR vmax / cm-1: 1736 (C=O str), 1518 (C=C 
str); 1H NMR δ (500 MHz, CDCl3) 7.92 (2H, d, J = 8.1 Hz, 2 × CH), 7.61 (2H, d, 
J = 8.3 Hz, 2 × CH), 4.18 (2H, s, NH2CH2), 1.90 (4H, q, J = 7.5 Hz, 2 × CH2), 1.08 
(6H, t, J = 7.5 Hz, 2 × CH3); 13C NMR δ (126 MHz, CDCl3) 173.22 (2 × C=O), 
135.59 (C), 132.95 (C), 131.28 (2 × CH), 120.71 (2 × CH), 73.51 (C), 43.83 (CH2), 
24.74 (2 × CH2), 9.42 (2 × CH3); HPLC (Method 1/ACN) tR = 3.05 min, purity 





5-Carboxyfluorescein (30 mg, 0.08 mmol) was added to anhydrous DMF (1 
mL), PyBrOP (56 mg, 0.12 mmol) and DIPEA (60 µL, 0.32 mmol) and stirred at 
rt for 15 min. To the reaction mixture 50 (20 mg, 0.08 mmol) was added and 
left to stir overnight (18 h). The reaction was monitored by HPLC and upon 
completion, DMF was removed in vacuo and the product purified using semi-






Yellow solid, yield: 0.015 g (31%); 1H NMR δ (600 MHz, MeOD) 8.49 (1H, m, 
ArH), 8.27 (1H, dd, J = 8.0, 1.6 Hz, ArH), 7.82 (2H, d, J = 8.5 Hz, ArH), 7.52 (2H, 
d, J = 8.5 Hz, ArH), 7.34 (1H, d, J = 8.0 Hz, ArH), 6.72 (2H, d, J = 2.4 Hz, ArH), 
6.63 (2H, d, J = 8.7 Hz, ArH), 6.57 (2H, dd, J = 8.7, 2.4 Hz, ArH), 4.67 (2H, s, 
CH2), 1.76 (4H, q, J = 7.6 Hz, 2 × CH2), 1.08 (6H, t, J = 7.5 Hz, 2 × CH3);  13C 
NMR δ (126 MHz, MeOD) 173.37 (C=O × 2), 170.55 (C=OO), 168.33 (C=ONH), 
161.47 (2 × C), 154.02 (2 × C), 138.89 (2 × C), 137.68 (C), 135.52 (CH), 134.07 (C), 
130.15 (2 × CH), 129.89 (C), 129.58 (2 × CH), 125.71 (CH), 124.90 (CH), 120.46 
(2 × CH), 113.62 (2 × CH), 110.83 (2 × C), 103.60 (2 × CH), 73.29 (C), 51.39 (C), 
44.32 (CH2), 24.78 (2 × CH2), 9.44 (2 × CH3); HPLC (Method 1/ACN) tR = 5.24 
min, purity 100% (ELSD); HRMS (ESI+, MeOH) [M+H]+ found 605.19090, 
C35H29O8N2 requires 605.19180. 
 
 3,3-Diethyl-1-(N-Cy5-benzylamino)-2,4-azetidinedione (52) 
27 (40 mg, 0.06 mmol) was added to HSPyU (25 mg, 0.06 mmol) and dissolved 
in dry DMF (2 mL) before DIPEA was added (30 µL, 0.18 mmol). The reaction 
was left to stir at rt for four hours until no starting material was observed. To 
the reaction mixture 50 (15 mg, 0.06 mmol) was added and additional DIPEA 
(30 µL, 0.18 mmol). The reaction was left to stir overnight. The reaction mixture 
was dried in vacuo and the crude product was purified by reverse phase 
chromatography (H2O/MeCN 95:5 → 70:30) with the product dried by freeze 






Dark blue solid, yield: 0.014 g, (27%); IR vmax / cm-1: 1736 (C=O str), 1183 (S=O 
str); 1H NMR δ (500 MHz, MeOD) 8.34 (2H, td, J = 13.1, 4.7, 1 Hz, 2 × CHar 
bridge), 7.94 (2H, s, 2CHar), 7.94-7.90 (2H, m, 2 CHar), 7.77 (2H, d, J = 8.6 Hz, 2 
× CHar), 7.40 (2H, d, J = 8.7 Hz, 2 × CHar), 7.39-7.34 (2H, m, 2 × CHar), 6.70 (1H, 
m, CHar bridge), 6.36 (2H, m, 2 × CHar bridge), 4.38 (2H, s, PhCH2), 4.20 (2H, q, J = 
7.1 Hz, NCH2), 4.14 (2H, t, J = 7.2 Hz, CH2), 2.30 (2H, t, J = 7.2 Hz, CH2), 1.83-
1.90 (2H, m, CH2), 1.85 (4H, q, J = 7.6 Hz, 2 × CH2), 1.77 (12H, s, 4 × CH3), 1.76 
(2H, m, CH2), 1.49 (2H, m, CH2), 1.42 (3H, t, J = 7.2 Hz, CH3), 1.05 (6H, t, J = 7.5 
Hz, 2 × CH3); 13C NMR δ (126 MHz, MeOD) 175.75 (C=O), 173.36 (2 × C=O), 
156.36 (CH), 156.14, 144.90 (C), 144.43(C), 142.76(C), 142.59(C), 139.10(C), 
133.94(C), 129.58 (2 × CH), 128.10 (2 × CH), 127.63 (CH), 121.44 (2 × CH), 120.42 
(2 × CH), 111.63 (CH), 111.45 (CH), 105.18 (CH), 104.98 (CH), 73.27 (C), 50.66 
(C), 50.58 (C), 45.00 (CH2), 43.66 (CH2), 40.28 (CH2), 36.57 (CH2), 28.08 (CH2), 
27.86 (2 × CH3), 27.72 (2 × CH3), 27.31 (CH2), 26.42 (CH2), 24.75 (2 × CH2), 12.52 
(CH3), 9.45 (2 × CH3); HPLC (Method 1/ACN) tR = 4.90 min, purity 100% 




Diethylmalonyl dichloride (0.87 mL, 5.07 mmol) was added to dry dioxane (5 
mL) and cooled to -10 °C. To the solution N-Boc-ethylenediamine (0.80 mL, 
5.07 mmol) was added in anhydrous dioxane (5 mL) over an hour. To the 
mixture NEt3 (4.7 mL) in dioxane was added slowly and then the reaction was 
left to stir at rt, for 18 h. The solid formed was filtered off, washed with hexane 
and the filtrate was dried in vacuo. The residue was purified using silica 
column chromatography (EtOAc: hexane, 1:4 → 100% EtOAc). This produced 






Colourless oil, yield: 0.342 g, (14%); IR vmax / cm-1: 3330 (N-H str), 1729 (C=O 
str); 1H NMR δ (500 MHz, CDCl3) 4.94 (1H, br s, NH), 3.45 (2H, m, CH2), 3.38 
(2H, m, CH2), 0.99 (4H, q, J = 7.5 Hz, 2 × CH2), 1.43 (9H, s, 3 × CH3), 0.99 (6H, t, 
J = 7.5 Hz, 2 × CH3); 13C NMR δ (126 MHz, CDCl3) 174.76 (2 × C=O), 164.45 
(C=O), 71.07 (C), 60.13 (C), 39.51 (CH2), 39.04 (CH2), 28.48 (3 × CH3), 23.55 (2 × 
CH2), 9.34 (2 × CH3); HPLC (Method 1/MeCN) tR = 4.06 min, purity 100% 




53 (0.342 g, 1.12 mmol) was added to anhydrous dioxane (4 mL) and to the 
solution, HCl in dioxane (4 M, 4 mL) was added. The reaction was left to stir 
for 4 h, after which a precipitate was observed. The mixture was filtered, and 
the precipitate was isolated and dried to produce 54 as a colourless solid (205 
mg, 98%).  
 
Colourless solid, yield: 205 mg, (98%); IR vmax / cm-1: 3359 (N-H str), 1722 (C=O 
str); 1H NMR δ (500 MHz, CDCl3) 8.48 (2H, br s, NH2), 3.87 (2H, t, J = 6.1 Hz, 
CH2), 3.42 (2H, t, J = 6.2 Hz, CH2), 1.80 (4H, q, J = 7.5 Hz, 2 × CH2), 0.99 (6H, t, 
J = 7.5 Hz, 2 × CH3); 13C NMR δ (126 MHz, CDCl3) 174.58 (2 × C=O), 70.64 (C), 
38.51 (CH2), 36.97 (CH2), 23.17 (2 × CH2), 9.23 (2 × CH3); HPLC (Method 
1/MeCN) tR = 3.78 min, purity 100% (ELSD); HRMS (ESI+, MeCN)  [M+Na]+ 







25 (21 mg, 0.044 mmol) was added to anhydrous DMF (1 mL) and DIPEA (11 
µL, 0.132 mmol) and 54 (8 mg, 0.044 mmol) and left to stir overnight. The 
reaction was monitored by HPLC and upon completion, DMF was removed 
in vacuo and the product purified using semi-preparative HPLC to yield 55 (12 
mg, 21%) as a yellow solid. 
 
Yellow solid, yield: 0.012 g (21%); Rf = 0.33 (DCM:MeOH:AcOH, 100:10:1); IR 
vmax / cm-1: 1728 (C=O str), 1605 (C=O str); 1H NMR δ (500 MHz, MeOD) 8.42 
(1H, m, ArH), 8.19 (1H, dd, J = 8.1, 1.7 Hz, ArH), 7.32 (1H, dd, J = 8.1, 0.7 Hz, 
ArH), 6.71 (2H, d, J = 2.3 Hz, ArH), 6.61 (2H, d, J = 8.7, ArH), 6.56 (2H, dd, J = 
8.7, 2.5 Hz, ArH), 3.69 (2H, m, CH2), 3.66 (2H, m, CH2), 1.76 (4H, q, J = 7.6 Hz, 
2 × CH2), 0.99 (6H, t, J = 7.5 Hz, 2 × CH3); 13C NMR δ (126 MHz, MeOD) 176.00 
(C=O × 2), 170.52 (C=OO), 168.76 (C=ONH), 161.56 (2 × C), 156.66 (2 × C), 
154.06 (2 × C), 137.70 (C), 135.45 (CH), 130.12 (2 × CH), 128.75 (C), 125.74 (CH), 
124.90 (CH), 113.74 (2 × CH), 110.86 (2 × C), 103.62 (2 × CH), 71.75 (C), 54.79 
(C), 39.55 (CH2), 39.10 (CH2), 9.44 (2 × CH3); HPLC (Method 1/ACN) tR = 4.54 
min, purity 100% (ELSD); HRMS (ESI+, MeOH) [M+H]+ found 543.17690, 







27 (54 mg, 0.08 mmol) was added to HSPyU (36 mg, 0.08 mmol) and dissolved 
in dry DMF (2 mL) before DIPEA was added (40 µL, 0.24 mmol). The reaction 
was left to stir for four hours until no starting material was observed. To the 
reaction mixture 54 (15 mg, 0.08 mmol) was added and additional DIPEA (40 
µL, 0.24 mmol). The reaction was left to stir at rt overnight. The reaction 
mixture was dried in vacuo and the crude product was purified by reverse 
phase chromatography with the product dried by freeze drier to yield 56 as a 
dark blue solid (31 mg, 45%). 
 
Dark blue solid, yield: 0.031 g (45%); IR vmax / cm-1: 1728 (C=O str), 1605 (C=O 
str); 1H NMR δ (600 MHz, MeOD) 8.35 (2H, t, J = 13.8 Hz, Arbridge), 7.92 (4H, 
m, ArH), 7.38 (2H, t, J = 8.5 Hz, ArH), 6.71 (1H, t, J = 12.4 Hz, Arbridge), 6.61 (2H, 
d, J = 13.7 Hz, Arbridge), 4.21 (2H, q, J = 7.2 Hz, NCH2), 4.16 (2H, t, J = 7.4 Hz, 
NCH2), 3.50 (2H, m, CH2), 3.41 (2H, m, CH2), 2.22 (2H, t, J = 7.3 Hz, COCH2), 
1.85 (2H, m, CH2), 1.78 (6H, s, 2 × CH3), 1.78 (6H, s, 2 × CH3), 1.77 (4H, q, J = 
7.5 Hz, 2 × CH2), 1.72 (2H, m, CH2), 1.50 (2H, m, CH2), 1.42 (3H, t, J = 7.3 Hz, 
CH2CH3), 1.00 (6H, t, J = 7.5 Hz, 2 × CH3); 13C NMR δ (126 MHz, MeOD) 176.23 
(C), 175.95 (C=O × 2), 175.31 (C), 175.04 (C), 156.34 (CH), 156.23 (CH), 144.92 
(C), 144.43 (C), 143.47 (C), 143.41 (C), 142.74 (C), 142.61(C), 128.10 (CH), 128.06 
(CH), 127.65 (CH), 121.41 (CH), 121.36 (CH), 111.66 (CH), 111.40 (CH), 105.21 
(CH), 104.92 (CH), 71.68 (C), 50.64 (C), 50.59 (C), 45.01 (CH2), 40.25 (CH2), 39.26 
(CH2), 38.72 (CH2), 36.67 (CH2), 28.12 (CH2), 27.84 (2 × CH3), 27.72 (2 × CH3), 





(Method 1/ACN) tR = 4.02 min, purity 100% (ELSD); HRMS (ESI+, MeCN) 
[M+H]+ found 823.33810, C42H55O9N4S2+ requires 823.34050. 
 
 (1R-Carbamoyl-3-methylsulfanyl-propyl)carbamic acid tert-butyl ester 
(62)115 
(R)-Methionine (2.50 g, 16.8 mmol), 1,4-dioxane (10 mL) and 1.25 M NaOH (13 
mL) were added to a round bottom flask and cooled to 0–6 °C. A solution of 
di-tert-butyl-dicarbonate (3.84 g, 17.6 mmol) in 1,4-dioxane (3 mL) was slowly 
added over 15 min, and the reaction was slowly warmed to room temperature 
and stirred for 3.5 h. 1,4-Dioxane was removed in vacuo and the residue was 
diluted using 1 M KHSO4 (17 mL), and washed with EtOAc (3 × 100 mL). The 
organic extracts were collected and washed with water (150 mL) and brine 
(100 mL) before being dried using MgSO4. The solvent was removed in vacuo 
to produce a pale-yellow oil, which was diluted in DMF (7 mL). To the solution 
was added ammonium bicarbonate (1.46 g, 18.47 mmol), pyridine (0.63 mL) 
and di-tert-butyl-dicarbonate (4.02 g, 18.5 mmol) dissolved in DMF (2 mL). 
Effervescence was exhibited and the mixture was left to stir at room 
temperature for 18 h. Water was added (100 mL) and extracted using EtOAc 
(3 × 50 mL), and the organic extracts were washed again with brine (2 × 100 
mL) and dilute H2SO4 solution (100 mL) before being dried using MgSO4 and 
the solvent removed in vacuo. The crude white solid was triturated in Et2O (50 
mL) for 20 min, before filtration and purification using silica column 
chromatography (EtOAc: cyclohexane, 1:1). This produced 62 (2.09 g, 50%) as 






Colourless solid, yield: 2.09 g, (50%). mp 120-22 °C, lit 118-9 °C; IR vmax / cm-1: 
3393 (N-H str), 3346 (N-H str), 1679 (C=O str), 1640 (C=O str); 1H NMR δ (500 
MHz, CDCl3) 6.39 (1H, br s, NH), 5.85 (1H, br s, NH), 5.31 (1H, m, NH), 4.31 
(1H, m, CH), 2.57 (2H, t, J = 7.4 Hz, CH2SCH3), 2.10 (3H, s, SCH3), 1.92 (2H, m, 
CH2), 1.43 (9H, s, CH3); 13C NMR δ (126 MHz, CDCl3) 174.25 (C), 155.82 (C), 
80.40 (C), 53.16 (CH), 31.77 (CH2), 30.35 (CH2), 28.45 (3 × CH3), 15.46 (CH3). 
The spectroscopic data is in agreement with the literature.115 
 
(2R-tert-Butoxycarbonylamino-4-methylsulfanyl-butyryl)-carbamic acid 
benzyl ester (63)115 
62 (4.40 g, 17.7 mmol) was dissolved in anhydrous THF (30 mL) and cooled to 
-70 °C. n-Butyllithium (14.2 mL, 35.4 mmol, 2.5 M in hexane) was added slowly 
over 10 min such that the temperature remained below -65 °C. To the reaction 
mixture was added benzyl chloroformate (2.5 mL, 17.7 mmol) and was left to 
stir at -65 °C for 1.5 h. To quench the reaction, aq. NH4Cl solution (15 mL) was 
added and left to warm to room temperature. The mixture was extracted with 
EtOAc (3 × 50 mL) which were then washed with brine (3 × 100 mL), dried 
using MgSO4 and the solvent removed in vacuo to produce a pale-yellow oil. 
The crude product was then purified using silica column chromatography 
(EtOAc: cyclohexane, 1:1). This produced 63 (6.19 g, 96%) as a pale-yellow oil.  
 
Pale yellow oil, yield: 6.19 g, (96%). IR vmax / cm-1: 3280 (N-H str), 2976 (C-Har 
str), 2918 (C-Halk str), 1771 (C=O str), 1686 (C=O str); 1H NMR δ (500 MHz, 
CDCl3) 8.66 (1H, br s, NH), 7.34 (5H, m, ArH), 5.31 (1H, br s, NH), 5.17 (2H, s, 
PhCH2O), 4.71 (1H, m, CH), 2.56 (2H, t, J = 7.4 Hz, CH3SCH2), 2.12 (1H, m, 





13C NMR δ (126 MHz, CDCl3) 172.05 (C), 155.96 (C), 150.88 (C), 134.97 (C), 
128.71 (3 × CH), 128.61 (2 × CH), 80.68 (C), 60.03 (CH2), 53.96 (CH), 31.59 (CH2), 
30.30 (CH2), 28.33 (3 × CH3), 15.47 (CH3). The spectroscopic data is in 
agreement with the literature.115 
 
(4-Benzyloxycarbonylamino-3R-tert-butoxycarbonylamino-4-oxo-butyl)-
dimethyl-sulfonium iodide (64)115 
63 (3.67 g, 10.1 mmol) was dissolved in acetone (5.7 mL) and iodomethane 
(3.11 mL, 50.3 mmol) was added. The reaction was left in the dark to stir for 3 
days. The solvent was removed in vacuo and the product was recrystallized 
using acetone and Et2O (1:20) to produce 64 as a pale yellow solid (2.86 g, 78%). 
 
Pale yellow solid, yield: 2.86 g, (78%). mp 129-131 °C, IR vmax / cm-1: 3383 (N-
H str), 3085 (C-Har str), 2952 (C-Har str), 1775 (C=O str), 1699 (C=O str); 1H 
NMR δ (500 MHz, CDCl3) 9.25 (1H, br s, NH), 7.38-7.31 (5H, m, HAr), 6.15 (1H, 
br s, NH), 5.16 (2H, s, PhCH2O), 4.79 (1H, br s, CH2CHNH), 3.97 (1H, m, 
CH2CH(H)), 3.55 (1H, m, CH2CH(H)), 3.24 (3H, s, SCH3), 3.19 (3H, s, SCH3), 
2.56 (1H, m, Me2SCH(H)), 2.22 (1H, m, Me2SCH(H)), 1.40 (9H, s, 3 × CH3); 13C 
NMR δ (126 MHz, CDCl3) 170.77 (C), 156.49 (C), 151.25 (C), 135.02 (C), 128.82 
(2 × CH), 128.75 (CH), 128.43 (2 × CH), 81.13 (C), 68.15 (CH2), 53.12 (CH), 41.43 
(CH2), 28.46 (3 × CH3), 27.60 (CH2), 26.41 (CH3), 26.14 (CH3).  
 






Amberlite IRA-410 chloride (1.00 g, 1.25 wt. eq.) was washed with NaOH 
solution (10 M, 3 × 10 mL), followed by a washing of H2O (2 × 10 mL), MeCN 
(2 × 10 mL) and Et2O (2 × 10 mL). The resin was added to 64 (0.75 g, 1.98 mmol) 
in acetonitrile (1.5 mL). After the addition of crushed and activated 4 Å 
molecular sieves (0.1 wt. eq., 0.075 g), the mixture was left to stir at 40 °C for 
4.5 h, during which further resin was added (0.25 g). The reaction was 
quenched by filtering the mixture, washing with EtOAc (3 × 25 mL). The 
solvent was removed in vacuo and recrystallized using cyclohexane: EtOAc 
(3.3:1) to produce 65 as a white solid (0.40 g, 64%). 
 
Pale yellow solid, yield: 0.40 g, (64%). mp 142 °C, lit115 139-41 °C; IR vmax / cm-
1: 3346 (N-H, str), 2975 (C-Har, str), 1774 (C=O, str), 1698 (C=O, str);  1H NMR δ 
(500 MHz, CDCl3) 7.43-7.33 (5H, m, ArH), 5.29 (2H, s, PhCH2O), 5.08 (1H, br s, 
NH), 4.27 (1H, br s, NHCHCH2), 3.90 (1H, dd, J = 10.5, 9.4 Hz, CH2CH(H)N), 
3.60 (1H, ddd, J = 11.5, 11.1, 6.4 Hz, CH2CH(H)N), 2.62 (1H, m, CH2CH(H)CH), 
1.89 (1H, m, CH2CH(H)CH), 1.45 (9H, s, 3 × CH3); 13C NMR δ (126 MHz, 
CDCl3) 171.79 (C), 155.70 (C), 151.32 (C), 135.17 (C), 128.77 (2 × CH), 128.66 
(CH), 128.37 (2 × CH), 80.55 (C), 68.51 (CH2), 53.73 (CH), 42.98 (CH2), 28.44 (3 
× CH3), 27.13 (CH2). The spectroscopic data is in agreement with the 
literature.115 
 
2-Oxo-3R-(2,2,2-trifluoro-acetylamino)pyrrolidine-1-carboxylic acid benzyl 
ester (66)115 
65 (0.41 g, 1.77 mmol) was dissolved in 1,4-dioxane (2 mL) and to the reaction 
2 M HCl in 1,4-dioxane (1.87 mL) was added and left to stir for 3.5 h. The 





to DCM (2.5 mL), MeOH (1 mL), methyl trifluoroacetate (0.89 mL, 8.83 mmol) 
and N-methyl morpholine (0.29 mL, 2.65 mmol) and was left to stir at rt for 18 
h. The reaction was quenched with DCM (10 mL), aq. 2 M HCl solution (10 
mL), and aq. 1 M NH4Cl solution (5 mL). The organic solvent was collected 
and washed with additional aq. 2 M HCl solution (15 mL), brine (2 x 25 mL) 
and dried using MgSO4. The solvent was removed in vacuo and the solid was 
triturated in Et2O: cyclohexane 1:1 (20 mL) for 20 min. The solid was filtered 
off and dried in a 40 °C vacuum oven for 18 h to produce 66 as a pale pink 
solid (0.27 g, 51%).  
 
Pale pink solid, 0.27 g, (51%); mp 157 °C, lit115 152-4 °C; IR vmax / cm-1: 3284 (N-
H, str), 1772 (C=O, str), 1714 (C=O, str), 1688 (C=O, str); 1H NMR δ (500 MHz, 
CDCl3) 7.42-7.33 (5H, m, ArH), 7.11 (1H, s, NH),  5.28 (2H, s, CH2O), 4.54 (1H, 
ddd, J = 12, 8.3, 6.0 Hz, NHCHCH2), 3.92 (1H, t, J = 10.7 Hz, CH2CH(H)N)  3.66 
(1H, td, J = 11.1, 6.4 Hz, CH2CH(H)N), 2.73 (1H, m, CH2CH(H)CH), 1.94 (1H, 
m, CH2CH(H)CH); 13C NMR δ (126 MHz, CDCl3) 170.32 (C), 158.21 (C-F), 
157.91 (C-F), 157.61 (C-F), 157.30 (C-F), 150.92 (C), 134.29 (C), 128.90 (CH), 
128.86 (2 × CH), 128.49 (2 × CH), 119.04 (C-F), 116.75 (C-F), 114.46 (C-F), 112.18 
(C-F), 68.90 (CH2), 52.86 (CH), 43.25 (CH2), 26.09 (CH2); ESI-MS (MeCN): m/z 
= 331.1 [M+H]+. The spectroscopic data is in agreement with the literature.115 
 
2-Ethoxy-3R-(2,2,2-trifluoro-acetylamino)pyrrolidine-1-carboxylic acid 
benzyl ester (67)115 
66 (3.5 g, 11 mmol) was added to anhydrous THF (30 mL) and after cooling to 
-40 °C, LiBH4 in THF (2M, 5.6 mL) was added slowly, and the reaction was left 





diluted with EtOH (10 mL) and to the solution, a mixture of H2SO4 and EtOH 
(3:10, 5.2 mL) was added slowly. The reaction was left to warm to room 
temperature over 2 h and upon completion, it was quenched with an aqueous 
NaHCO3 solution (1M, 30 mL). The ethanol was removed in vacuo and the 
aqueous mixture was extracted with EtOAc (3 × 100 mL). The organic layer 
was washed with brine (100 mL), dried using MgSO4 and concentrated in 
vacuo, to give the two ethers as an oil. 
 
Colourless oil, 3.80 g, (97%); 1H NMR δ (500 MHz, CDCl3) 7.37-7.32 (5H, m, 
ArH), 6.90-6.75 (1H, m, NH),  5.17-5.10 (3H, m), 4.30 (1H, m), 3.72-3.39 (4H, m),  
2.45-2.34 (1H, m), 1.94 (1H, m), 1.19-1.09 (3H, m); tR: 4.49 and 5.06 min (GE10 
MeCN, 254 nm); ESI-MS (MeCN): m/z = 360.1 [M+H]+. The spectroscopic data 
is in agreement with the literature.115 
 
Z-(1-Ethoxy-3-methyl-but-1-enyloxy)-triisopropyl-silane (68)115 
DMPU and THF (2:3, 35 mL) were mixed and cooled to -40 °C, before the 
addition of LiHMDS (1M in THF, 16 mL). The solution was cooled down to -
78 °C and ethyl isovalerate (3.05 mL, 0.020 mol) was added slowly, 
maintaining the internal temperature. After 1 h, tri-isopropyl triflate (5.43 mL, 
0.202 mol) was added slowly and the reaction was left to warm overnight. The 
reaction was quenched at 5 °C with aqueous 1M NaHCO3 solution (30 mL) and 
washed with hexane (4 × 25 mL), which was collected and washed with H2O 
(5 × 40 mL). The organic layer was collected, dried with MgSO4 and dried in 
vacuo to yield 68 as a crude product. 68 was then purified using vacuum 






Colourless liquid, 0.58 g, (10%); 1H NMR δ (500 MHz, CDCl3) 3.89 (0.2H, q, J = 
7.05 Hz, CH2CH3), 3.66 (2H, q, J = 7.05 Hz, CH2CH3), 3.20 (1H, d, J = 8.25 Hz, 
iPrCH), 2.59 (1H, m, C=CH), 1.26 (3H, t, J = 7.0 Hz, CH2CH3), 1.18 (3H, m, 3 × 
iPrCH) 1.07 (18H, m, 3 × CH(CH3)2), 0.96 (6H, d, J = 6.8 Hz, CH(CH3)2); 13C 
NMR δ (126 MHz, CDCl3) 154.69 (C), 82.79 (CH), 62.68 (CH2), 24.91 (2 × CH3), 
24.50 (CH), 18.08 (6 × CH3), 14.64 (CH3), 13.00 (3 × CH). The spectroscopic data 
is in agreement with the literature.115 
 
(2S,3R)-3-Amino-2-(Rel-1S-ethoxycarbonyl-2-methylpropyl) pyrrolidine-1-
carboxylic acid benzyl ester (71) 
67 (0.559 g, 1.55 mmol) was added to dry DCM (10 mL) and cooled to 5 °C 
before adding 68 (1.33 g, 4.65 mmol) and BF3.OEt2 (1.15 mL, 9.3 mmol) slowly 
to the solution, with the reaction monitored by HPLC (peaks at 5.37 min and 
5.71 min, ELSD). Upon completion, the reaction mixture was purified crudely 
to yield the ester 69. After this, 69 (599 mg, 1.35 mmol) was added to a mixture 
of EtOH and H2O (1:1, 10 mL) and K2CO3 (0.931 g, 1.35 mmol). The mixture 
was heated to reflux, and the reaction monitored by TLC and HPLC (peaks at 
3.36 min and 3.45 min, ELSD), and after the reaction was complete the EtOH 
was removed in vacuo and diluted with water (20 mL). The aqueous layer was 
washed with Et2O (3 × 40 mL), the organic layers collected and washed with 
1M HCl (3 × 100 mL). The acidic aqueous layers were collected and neutralised 
to pH 7/8 with Na2CO3, before the product was extracted with DCM (3 × 100 
mL). The DCM washes were collected and dried with MgSO4, and the solvent 
removed in vacuo.  
The amine 70 (103 mg, 0.30 mmol) was added to THF (1 mL) and TMEDA (1 





the reaction was left to warm to room temperature for 2 h. The reaction was 
quenched with saturated aqueous ammonium chloride (10 mL) and extracted 
with EtOAc (3 × 10 mL). The organic washings were collected, dried with 
MgSO4 and the solvent removed in vacuo. The crude mixture was purified 
using flash chromatography (2:8 cyclohexane: EtOAc → 100% EtOAc), to yield 
the 71a as a white solid (15.1 mg, 16%). 
 
Pale brown solid, yield: 0.015 g, (16%); IR vmax / cm-1: 3295 (N-H, str), 3068 
(C=C, str), 2920 (C-C, str); 1H NMR δ (600 MHz, CDCl3) 7.38-7.31 (5H, m, ArH), 
5.96 (1H, br s, NH), 5.13 (1H, d, J = 12.1 Hz, CO2CHH), 5.09 (1H, d, J = 12.1 Hz, 
CO2CHH), 3.81 (1H, m, CbzNCHH), 3.76 (1H, m, CbzNCHH), 3.21-3.16 (2H, 
m, 2 × NCH), 2.68-2.54 (2H, m, iPrCH, CH3CHCH3), 2.18 (1H, m, CH2CH(H)), 
1.76 (1H, m, CH2CH(H)), 1.14 (3H, br s, CH3) 0.95 (3H, br s, CH3); 13C NMR δ 
(150 MHz, CDCl3) 180.91 (C=O), 155.25 (C=O), 136.28 (C), 128.68 (2 × CH), 
128.57 (2 × CH), 128.40 (CH), 67.35 (CH2), 65.68 (CH), 58.35 (CH), 54.80 (CH), 
49.78 (CH2), 27.50 (CH2), 26.12 (CH), 21.32 (CH), 16.71 (CH); tR: 4.79 min (GE10 
MeCN, 254 nm); HRMS (ESI+, MeCN) [MH]+ found 302.16329, C17H22O3N2 




b] pyrrole-1-carboxylic acid benzyl ester (72) 
To 71a (60 mg, 0.20 mmol) dissolved in dry THF (1 mL) and cooled down to -





for 1 hr, before methanesulfonyl chloride (38 µL, 0.50 mmol) was added 
slowly, with the reaction temperature being monitored. After the reaction was 
complete, the reaction was quenched with aqueous NaHCO3 (5 mL) and 
slowly warmed to room temperature. The product extracted with DCM (2 × 
10 mL), and the combined extracts were then washed with brine (2 × 10 mL), 
dried with MgSO4 and the solvent removed in vacuo. The crude product was 
purified using silica column chromatography (EtOAc: hexane, 1:4). This 
produced 72 (0.40 g, 20%) as a pale-yellow oil.  
 
Colourless solid, yield: 0.035 g, (50%); IR vmax / cm-1: 3295 (N-H, str), 3068 (C=C, 
str), 2920 (C-C, str); 1H NMR δ (500 MHz, CDCl3) 7.39-7.32 (5H, m, ArH), 5.13 
(1H, d, J = 12.1 Hz, CO2CHH), 5.09 (1H, d, J = 12.1 Hz, CO2CHH), 3.84 (1H, m, 
CbzNCHH), 3.78 (1H, m, CbzNCHH), 3.47 (1H, m, (SO2Me)NCH), 3.27 (1H, 
m, NCH), 3.24 (3H, br s, (NSO2)CH3), 2.78-2.64 (2H, m, iPrCH, CH3CHCH3), 
2.55 (1H, m, CH2CH(H)), 2.02 (1H, m, CH2CH(H)), 1.15 (3H, br s, CH3) 0.95 
(3H, br s, CH3); 13C NMR δ (126 MHz, CDCl3) 176.26 (C=O), 155.12 (C=O), 
136.03 (C), 128.76 (4 × CH), 128.56 (CH), 67.63 (CH2), 63.34 (CH), 61.74 (CH), 
55.98 (CH), 49.42 (CH2), 40.99 (CH3), 28.25 (CH2), 26.54 (CH), 21.04 (CH3), 16.36 
(CH3); (Method 1/MeCN) tR: 5.20 min (254 nm); HRMS (ESI+, MeCN)  [MH]+ 
found 381.14880, C18H25O5N232S1 requires 381.14787. The spectroscopic data is 









72 (0.035 g, 0.091 mmol) was dissolved in EtOAc: dioxane (1:1, 3 mL) and was 
flushed with N2, before the addition of Pd(OH)2/C (8 mg, 0.011 mmol). The 
mixture was left to stir under H2 for 3 h, monitoring the reaction until 
completion. The reaction mixture was filtered through celite, keeping the filter 
cake damp, and washed through with EtOAc (2 × 15 mL). The solvent was 
removed in vacuo to produce 59 as a pale-yellow oil (0.014 g, 63%)  
 
Pale yellow oil, yield: 0.014 g, (63%); 1H NMR δ (400 MHz, CDCl3): 3.54 (1H, 
td, J = 10.9, 2.1 Hz, HNCHH), 3.39 (2H, m, HNCHH, CHN(SO2Me)), 3.23 (3H, 
s, (NSO2)CH3), 2.99 (1H, br s, NH), 2.94 (1H, dd, J = 12.3, 9.5 Hz, CHNHCH2), 
2.41 (2H, m, iPrCH, NHCH2CH(H)), 2.23 (1H, m, CH3CHCH3), 1.93 (1H, m, 
NHCH2CH(H)), 1.10 (3H, d, J = 6.9 Hz, CH3) 0.96 (3H, d, J = 6.9 Hz, CH3); 13C 
NMR δ (101 MHz, CDCl3) 177.48 (C=O), 64.60 (CH), 63.64 (CH), 56.90 (CH), 
48.30 (CH2), 40.89 (CH3), 28.26 (CH2), 26.73 (CH), 21.14 (CH3), 19.03 (CH3); tR: 
5.20 min (GE10 MeCN, 254 nm); HRMS (ESI+, MeCN) [MH]+ found 247.1126, 
C10H19O3N232S1 requires 247.1111. The spectroscopic data is in agreement with 
the literature.115 
 
(E)-Piperazidyl-1-ylbut-2-enoic acid (73) 
(E)-4-Boc-piperazidyl-1-ylbut-2-enoic acid ethyl ester (1.438 g, 7.25 mmol) was 
added to dioxane (10 mL) and to it was added 4M HCl in dioxane (10 mL) and 
water (2 mL) and was left to reflux for 3 hours. The solvent was removed in 
vacuo and the crude product was diluted with water (2 mL) and to it MeOH 
was added, to give a white precipitate. The precipitate was filtered off and 






Colourless solid, yield: 0.23 g, (30%); IR vmax / cm-1: 2912 (N-H, str), 2250 (O-H, 
str), 1705 (C=O, str), 1652 (C=C, str); 1H NMR δ (600 MHz, D2O) 6.90 (1H, dt, J 
= 15.6, 7.3 Hz, CH), 6.37 (1H, d, J = 15.6 Hz, CH), 4.11 (2H, dd, J = 7.3, 1.1 Hz, 
NCH2), 3.66 (8H, m, 4 × CH2); 13C NMR δ (151 MHz, D2O) 168.61 (C=O), 133.74 
(CH), 131.03 (CH), 56.82 (CH2), 48.38 (2 × CH2), 40.90 (2 × CH2); HRMS (ESI+, 
MeCN) [MH]+ found 171.1131, C8H15N2O2 requires 171.1128. 
 
(E)-4-Boc-piperazidyl-1-ylbut-2-enoic acid ethyl ester (75) 
Ethyl-4-bromocrotonate (1 mL, 7.25 mmol) was added to N-Boc piperazine 
(1.46 g, 7.87 mmol) and diluted with acetonitrile (15 mL). To the mixture 
potassium carbonate (1.08 g, 7.87 mmol) was added slowly to maintain low 
temperature inside the flask. The reaction was left to stir for 18 h before 
removing the solvent in vacuo and the residue re-dissolved in H2O and EtOAc 
(1:1, 40 mL). The aqueous layer was washed with EtOAc (2 × 10 mL), the 
organic extracts were collected, dried with MgSO4 and the solvent removed in 
vacuo. The pale-yellow residue was purified using column chromatography 
(DCM → 10% MeOH) to yield 75 as a pale-yellow oil (1.37 g, 63%).  
 
Pale yellow oil, yield: 1.37 g, (63%); Rf: 0.59 (DCM: MeOH 90:10); 1H NMR δ 
(500 MHz, CDCl3) 6.91 (1H, dt, J = 15.7, 6.1 Hz, CH), 5.97 (1H, dt, J = 15.7, 1.5 
Hz, CH), 4.18 (2H, q, J = 7.1 Hz, C=OCH2), 3.43 (4H, m, 2 × CH2), 3.12 (2H, dd, 
J = 6.2, 1.6 Hz, NCH2), 2.39 (4H, m, 2 × CH2), 1.44 (9H, s, 3 × CH3) 1.28 (3H, t, J 
= 7.1 Hz, CH3); 13C NMR δ (151 MHz, CDCl3) 166.21 (C=O), 154.81 (C=O), 
144.69 (CH), 123.72 (CH), 79.81 (C), 60.54 (CH2), 59.38 (CH2), 53.16 (2 × CH2), 





nm); HRMS (ESI+, MeCN) [MH]+ found 299.19620, C15H27N2O4 requires 
299.19653. 
 
(E)-Piperazidyl-1-ylbut-2-ene ethyl ester (76) 
(E)-4-Boc-piperazidyl-1-ylbut-2-enoic acid ethyl ester (75) (1.37 g, 4.59 mmol) 
was added to dioxane (10 mL) and to it was added 4N HCl in dioxane (10 mL) 
and EtOH (5 mL) and was left to reflux for 4 hours. The solvent was removed 
in vacuo to give the product as a pale yellow solid (1.117 g, 108%). 
 
Colourless solid, yield: 1.117 g, (108%); Rf: 0.24 (DCM: MeOH 90:10); 1H NMR 
δ (500 MHz, MeOD) 7.01 (1H, dt, J = 15.6, 7.2 Hz, CH), 6.42 (1H, dt, J = 15.6, 1.3 
Hz, CH), 4.26 (2H, q, J = 7.1, Hz, CH2), 4.16 (2H, dd, J = 7.3, 1.4 Hz, NCH2), 3.69 
(8H, m, 4 × CH2), 1.33 (3H, t, J = 7.1 Hz, NCH2); 13C NMR δ (151 MHz, MeOD) 
166.05 (C=O), 134.42 (CH), 132.09 (CH), 62.20 (CH2), 57.77 (CH2), 49.54 (2 × 
CH2), 42.05 (2 × CH2), 14.45 (CH3); HRMS (ESI+, MeCN) [MH]+ found 
199.1438, C10H19N2O2 requires 199.1441. 
 
4-Bromo-butenoic acid (77) 
Ethyl-4-bromocrotonate (2 mL, 14.6 mmol) was added to a mixture of H2O and 
EtOH (1:1, 50 mL) and K2CO3 (2.15 g, 15.6 mmol) and the reaction was left to 
react for 6 h. Ethanol was removed in vacuo and the aqueous mixture was 
washed with EtOAc (2 × 150 mL), before being acidified to pH 1 with HCl. The 
aqueous layer was then washed with EtOAc (3 × 60 mL), the organic washings 
collected and dried with MgSO4 and solvent removed in vacuo to produce 77 







Pale yellow oil, yield: 0.473 g, (20%); IR vmax / cm-1: 3062 (O-H br, str), 1684 
(C=O, str), 1632 (C=C, str), 688 (CH2-Br, str); 1H NMR δ (500 MHz, D2O) 7.10 
(1H, dt, J = 15.3, 7.4 Hz, CH), 6.13 (1H, d, J = 15.4 Hz, CH), 4.17 (2H, dd, J = 7.4 
Hz, CH2); 13C NMR δ (500 MHz, D2O) 169.79 (C=O), 144.15 (CH), 123.59 (CH), 
29.45 (CH2); HPLC (Method 1/ACN) tR = 2.98 min, purity 100% (ELSD); ESI-
MS (MeCN): m/z = 165.1 [M+H]+. 
 
Resin bound (E)-piperizin-1-yl-but-2-enoic acid (79) 
Chlorotrityl resin (1.00 g, 1 mmol) was swollen with dry DCM (3 × 15 mL) in 
an N2 atmosphere and to it thionyl chloride (0.18 mL, 2.5 mmol) was added in 
DCM (15 mL) and left to react for 1 h. The mixture was rinsed off, and the resin 
washed with DMF (15 mL) and DCM (15 mL). 4-Bromo-butenoic acid (0.454 
g, 2.75 mmol) was dissolved in DMF (12 mL) and added to the resin for 2 h. 
The addition was confirmed by cleaving a sample (<0.01 mmol) with 20% 
HFIP in DCM (1 mL) and analysing the crude product on HPLC. The resin was 
washed with DMF (2 × 15 mL) and DCM (2 × 15 mL). To the resin, a solution 
of piperazine (0.43 g, 5.00 mmol) in DMF (12 mL) was added and left to stir for 
2 h. Reaction completion was determined by the chloroanil test on a sample of 
resin. The excess piperazine was removed by rigorous washing with DMF (3 
× 15 mL) and the resin stored in the fridge after swelling and drying the resin 










27 (0.182 g, 0.28 mmol) was added to HSPyU (0.114 g, 0.28 mmol) and 
dissolved in dry DMF (10 mL) before DIPEA was added (0.15 mL, 0.83 mmol). 
The reaction was left to stir for 5 h until no starting material was observed. The 
resin containing 79 (0.3 g, 0.3 mmol resin) was swelled with DCM (3 × 10 mL), 
and to it the reaction mixture was added and additional DIPEA (0.15 mL, 0.83 
mmol). The reaction was left to stir overnight, and the excess dye was 
removed. The resin was washed repeatedly, alternating between DMF (10 mL) 
and DCM (10 mL) until the run off was clear. The resin beads were swollen 
with DCM (3 × 10 mL) and the product was cleaved from the beads in a 
solution of 20% HFIP in DCM (v/v) (10 min, 4 × 5 mL). The solution was dried 
in vacuo and the crude product purified by reverse phase chromatography 
(H2O/MeCN 95:5 → 70:30) with the product dried by lyophilisation to yield 
80 as a dark blue solid (17 mg, 8%). 
 
 
Dark blue solid, yield: 0.017 g, (8%); 1H NMR δ (500 MHz, DMF-d7:D2O, 4:1) 





8.1 Hz, 2 × CHar), 7.49-7.43 (2H, m, 2 × CHar), 6.93 (1H, dt, J = 15.5, 6.6 Hz, 
CH2CH=CH), 6.80 (1H, t, J = 12.3 Hz CHbridge), 6.50 (2H, d, J = 13.7 Hz, 2 × CHar), 
6.17 (2H, d, J = 15.7 Hz, 2 × CHar), 2.85-2.79 (4H, m, 2 × NCH2), 2.46 (2H, t, J = 
7.2 Hz, COCH2), 1.93-1.87 (2H, m, CH2), 1.78 (6H, s, 2 × CH3), 1.78 (6H, s, 2 × 
CH3), 1.70-1.65 (2H, m, CH2), 1.54-1.50 (2H, m, CH2), 1.42 (3H, t, J = 6.6 Hz, 
CH3); 13C NMR δ (500 MHz, DMF-d7:D2O, 4:1) 173.65 (C), 173.51 (C), 172.02 
(C=O), 167.19 (C=ONR), 154.66 (CH), 154.44 (CH), 144.04 (C), 143.80 (C), 
143.08 (C), 142.46 (C), 141.26 (C), 141.11 (C), 141.06 (CH), 126.70 (CH), 126.66 
(CH), 126.47 (CH), 126.34 (CH), 120.13 (CH), 120.09 (CH), 110.61 (CH), 110.35 
(CH), 103.98 (CH), 103.78 (CH), 57.62 (CH2), 52.54 (NCH2), 52.17 (NCH2), 49.28 
(C), 49.18 (C), 44.20 (NCH2), 43.84 (CH2), 40.20 (NCH2), 39.17 (CH2), 32.08 
(CH2), 26.96 (2 × CH3), 26.91 (CH2), 26.80 (2 × CH3), 25.92 (CH2), 24.79 (CH2), 
11.86 (CH3); HPLC (Method 1/ACN) tR = 3.16 min, purity 100% (ELSD); 






oxo-hexahydro-pyrrolo [3,2-B] pyrrol-2-one (81) 
80 (10.0 mg, 0.012 mmol) was added to EDC.HCl (4.6 mg, 0.024 mmol) and 
HOBt (3.3 mg, 0.024 mmol) dissolved in dry DMF (0.5 mL) before TEA was 
added (3 µL, 0.024 mmol). The reaction was left to stir at rt for five hours until 
no starting material was observed. To the reaction mixture 59 (3.0 mg, 0.012 
mmol) was added and additional TEA (3 µL, 0.024 mmol). The reaction was 
left to stir overnight. The reaction mixture was dried in vacuo and the crude 
product was purified by reverse phase chromatography (H2O/MeCN 95:5 → 
70:30) with the product dried by freeze drier to yield 81 as a dark blue solid 






Dark blue solid, yield: 1.2 mg, (10%); 1H NMR δ (600 MHz, MeOD) 8.38-8.30 
(1H, m, CHbridge), 7.94-7.86 (4H, m, CHar), 7.36 (2H, d, J = 8.2 Hz, 2 × CHar), 6.84-
6.75 (2H, m, 2 × CHbridge), 6.74-6.65 (1H, m, CH=CHCO), 6.44 (1H, d, J = 15.3 
Hz, CH=CHCO), 6.36 (2H, m, 2 × CHbridge), 4.20 (2H, q, J = 7.2 Hz, NCH2), 4.16 
(2H, t, J = 7.2 Hz, NCH2), 3.97 (2H, m, CONCH2), 3.70-3.63 (1H, m, 
CHNSO2Me), 3.62-3.58 (2H, m, NCH2), 3.57-3.53 (2H, m, NCH2), 3.49-3.39 (1H, 
m, CHNCH2), 3.26 (3H, s, SO2CH3), 3.23-3.20 (2H, m, CH2CH=CH), 3.01 (1H, 
br s, CH(CH3)2), 2.95 (1H, m, iPrCH), 2.57-2.50 (1H, m, NCH2CH(H)), 2.50-2.45 
(2H, m, NCH2), 2.45-2.38 (4H, m, CH2, NCH2), 2.19-2.09 (1H, m, NCH2CH(H)), 
1.86 (2H, p, J = 7.6 Hz, CH2), 1.77 (2H, m, CH2), 1.77 (6H, s, 2 × CH3), 1.77 (6H, 
s, 2 × CH3), 1.73-1.65 (2H, m, CH2), 1.50-1.45 (2H, m, CH2), 1.41 (3H, d, J = 7.2 
Hz, CH2CH3), 1.28 (3H, d, J = 7.2 Hz, CH(CH3)(CH3)), 1.02 (3H, d, J = 6.9 Hz, 
CH(CH3)(CH3)); 13C NMR δ (126 MHz, MeOD) 175.11 (C), 173.66 (C), 170.37 
(C), 155.80 (CH), 145.60 (C), 144.95 (C), 144.40 (C), 144.12 (C), 143.55 (C), 142.99 
(CH), 142.60 (C), 131.40 (C), 130.87 (C), 128.09 (2 × CH), 127.62 (C), 127.51 (C), 
125.10 (CH), 121.42 (2 × CH), 111.41 (2 × CH), 104.92 (2 × CH), 66.65 (CH2), 
65.26 (CH), 61.76 (CH), 59.95 (CH2), 56.62 (CH), 56.44 (CH), 54.34 (CH2), 53.84 
(CH2), 50.67 (C), 50.60 (C), 46.64 (CH2), 45.02 (CH2), 42.63 (CH2), 40.28 (CH2), 
39.78 (CH3), 33.40 (CH2), 29.51 (CH2), 28.23 (CH2), 27.87 (2 × CH3), 27.73 (2 × 
CH3), 27.42 (CH2), 26.04 (CH2), 21.63 (CH3), 16.56 (CH3), 12.52 (CH3); HPLC 
(Method 1/ACN) tR = 3.58 min (ELSD); HRMS (ESI+, MeCN)  [M+Na]+ found 






5.3 Biological methods 
 
5.3.1 HNE IC50 determination 
The substrate MeOSuc-Ala-Ala-Pro-Val-AMC (Sigma Aldrich, 15 µL, 2.667 
mM, 10% DMSO in 0.5 M PBS buffer, final concentration 1 mM) was added to 
serial dilutions of probe 81 (15 µL, 10 µM to 156.25 nM) and to the mixture 
within the plate, the enzyme HNE was added (EPC Ltd., 10 µL of 200 nM 
solution, in 50% PBS 50% gylcerol, pH 5.5, with a final concentration of 50 nM). 
The fluorescence of the cleaved substrate was monitored over 20 minutes at 
460 nm, upon excitation at 360 nm. The positive control contained only 
substrate and enzyme, and buffer (1:1000 v/v, DMSO in buffer), and the 
negative control contained no enzyme and only PBS buffer. The progress 
curves generated were analysed to generate IC50 values. 
 
5.3.2 HNE Ki determination 
The substrate MeOSuc-Ala-Ala-Pro-Val-pNA (Sigma Aldrich, 20 µL of 10 mM 
20% DMSO in 0.1 M HEPES, final concentration 1 mM) was added to serial 
dilutions of probe 81 (10 µL, 10 µM to 156.25 nM) and diluted with 150 µL of 
0.1 M HEPES (pH 7.4). To the mixture HNE was added (EPC Ltd., 20 µL of 300 
nM solution, in 50% PBS 50% gylcerol, pH 5.5, to a final concentration of 30 
nM). The fluorescence of the cleaved substrate was monitored over 20 min at 
460 nm, upon excitation at 360 nm. The positive control contained only 
substrate and enzyme, and buffer (1:1000 v/v, DMSO in buffer), where the 
negative control contains no enzyme and only buffer. The progress curves 






5.3.3 Stability study in buffer 
PBS (1 M, pH 7.4, 2.5 mL) was warmed to 37 °C, and probe was added to give 
a concentration of  (25 µL, 10 mM) was added, aliquots of 100 µL were taken 
at regular time points and analysed via analytical HPLC at 650 nm or at 254 
nm.  
 
5.3.4 Stability study in media 
Dulbecco's Modified Eagle's Medium (DMEM) media was warmed to 37 °C, 
and to a volume of 2.475 mL, the probe (25 µL, 10 mM) was added to give a 
final concentration of 100 µM. Aliquots of 100 µL were taken at regular time 
points over 10 h, added to acetonitrile (100 µL) (to crash out proteins). The 
mixture was centrifuged at 7.4 g for 4 min, the supernatant collected, filtered 
and analysed via analytical HPLC at 650 nm or 254 nm. 
 
5.3.5 Confocal microscopy 
Neutrophils were purified from a human blood sample using the Percoll 
preparation.108 An eight-chamber microscope slide (Ibidi Tech.) was incubated 
in a fibronectin solution for 30 min at 37 °C. The neutrophils were isolated, and 
200000 cells were plated in each well. They were incubated with Dulbecco’s 
PBS (Gibco, containing CaCl2 and MgCl2, pH 7.4) for 0.5 h, before being 
washed and then incubated with HOECHST 33342 (10 µg/mL) for 15 min. The 
cells were washed with PBS and the probes were added (500 nM, diluted from 
10 mM stock solution in DMSO). The cells were then imaged, without a wash 
step, the calcium ionophore (5 µM, 2 min) was added, and the neutrophils 
were imaged again. Leica SP8 Confocal microscope laser settings were: 
excitation laser lines at 488 nm and 633 nm with emission filters of 414-464 nm 
for HOECHST 33342, 506-530 nm for fluorescein-based optical probes and 638-






5.3.6 Flow cytometry  
Neutrophils (4 000000 from the Percoll prep108) were separated into two 
populations: one to be activated and the other unactivated. Both populations 
were incubated in Dulbecco’s PBS (Gibco, containing CaCl2 and MgCl2, pH 
7.4) for 0.5 h. The unactivated were with PBS buffer and divided with one half 
treated with the probe. The activated population were incubated with a 
calcium ionophore (1 µM) for 10 min before being washed and divided with 
one sample the control and the other had the probe added. Cells were pelleted, 
washed with PBS, reconstituted and to all samples a neutrophil specific CD66b 
antibody labelled with phycoerythrin (BD biosciences) added and incubated 
with the cells for 15 min. The cells were then pelleted again, washed with PBS, 
and reconstituted in FACS buffer (5% foetal bovine serum in PBS). 
Immediately before measuring on the flow cytometer, the cells were stained 
with DAPI to elucidate the viability of the cells.  
 
5.3.7 Haemolysis toxicity assay 
For the determination of haemolysis by the compounds, a standard solution 
of 14% human erythrocytes in PBS (pH 7.4) diluted 1:1 with the compounds in 
solution. The probes were diluted in DMSO and PBS buffer at two 
concentrations (100 nM and 10 µM, to give final lysis concentrations of 50 nM 
and 5 µM). A control of 7% erythrocyte solution in PBS was used to determine 
baseline lysis. The mixtures were incubated at 37 °C for 1 h and centrifuged at 
400 g for 5 min. The supernatant was removed and the absorbance at 415 nm 
was measured, with the data normalised to the probe in PBS to account for 






To generate the control percentage of lysis, a serial dilution of 7% erythrocyte 
solution (100% lysis) to 0.03% erythrocyte solution (0.4% lysis). The solutions 
were sonicated for 15 sec at 5 mW power, to ensure complete lysis and spun 
down using a centrifuge at 400 g for 5 min. The supernatant was removed and 
the absorbance at 415 nm was measured, with the data normalised to the probe 
in PBS to account for background absorbance.  
 
5.3.8 Gel electrophoresis 
The samples were mixed with two times concentrated sample buffer (2x 
Laemmli Sample Buffer, 1:1 v/v) with 50 mM DTT and heated for 5 min at 80 
°C. The samples were then were loaded onto 12% (wt./v) polyacrylamide gel 
and run at a voltage of 120 V for 20 min, followed by 160 V for 40 min using a 
BIO RAD PowerPac 300 power supply. The gel was imaged in fluorescein and 
cy5 channels before being stained with Coomassie Blue (0.006% wt./v AcOH 
in water (1:9)) for 2 h. The stained gel was washed several times with water 





Chapter 6 References 
 
1 A. Hessenbruch, Endeavour, 2002, 26, 137–141. 
2 T. Hussain and Q. T. Nguyen, Adv. Drug Deliv. Rev., 2014, 66, 90–100. 
3 L. Schrievens, N. Lorent, C. Dooms and J. Vansteenkiste, Oncologist, 
2004, 9, 633–643. 
4 S. Khondee and T. Wang, J. Healthc. Eng., 2013, 4, 1–22. 
5 H. Lusic and M. W. Grinstaff, Chem. Rev., 2013, 113, 1641–1666. 
6 J. I. Bloch, E. T. Chou and J. A. Carrino, Pain Manag., 2007, 106–117. 
7 E. M. Gale and P. Caravan, ACS Chem. Neurosci., 2018, 9, 395–397. 
8 M. M. Khalil, J. L. Tremoleda, T. B. Bayomy and W. Gsell, Int. J. Mol. 
Imaging, 2011, 2011, 1–15. 
9 S. Liu, D. S. Edwards and J. A. Barrett, Bioconjug. Chem., 1997, 8, 621–
636. 
10 D. D. Nolting, M. L. Nickels, N. Guo and W. Pham, Am. J. Nucl. Med. 
Mol. Imaging, 2012, 2, 273–306. 
11 S. a Hilderbrand and R. Weissleder, Curr. Opin. Chem. Biol., 2010, 14, 
71–79. 
12 P. B. Garcia-Allende, M. Koch, J. Glatz, P. Symvoulidis and V. 
Ntziachristos, Opt. Mol. Probes, Imaging Drug Deliv., 2015, OW1D--1. 
13 J. . R. Widengren R., Bioimaging, 1996, 4, 149–157. 
14 J. R. Lakowicz, Principles of Fluorescence Spectroscopy Principles of 
Fluorescence Spectroscopy, Springer Science, 2006. 





Rev., 2010, 110, 2620–2640. 
16 W. Stummer, U. Pichlmeier, T. Meinel, O. D. Wiestler, F. Zanella and 
H.-J. Reulen, Lancet Oncol., 2006, 7, 392–401. 
17 J. T. Alander, I. Kaartinen, A. Laakso, T. Pätilä, T. Spillmann, V. V. 
Tuchin, M. Venermo and P. Välisuo, Int. J. Biomed. Imaging, 2012, 2012, 
1–12. 
18 M. Hutteman, A. L. Vahrmeijer, J. R. van der Vorst, P. J. K. Kuppen, C. 
W. G. M. Löwik, C. J. H. van de Velde, B. E. Schaafsma, J. V. Frangioni 
and J. S. D. Mieog, J. Surg. Oncol., 2011, 104, 323–332. 
19 M. Taniguchi and J. S. Lindsey, Photochem. Photobiol., 2018, 94, 290–327. 
20 T. J. Russin, E. İ. Altinoğlu, J. H. Adair and P. C. Eklund, J. Phys. 
Condens. Matter, 2010, 22, 334217. 
21 T. Robertson, F. Bunel and M. Roberts, Cells, 2013, 2, 591–606. 
22 R. Agrawal, S. B. B. Tun, P. K. Balne, H. Y. Zhu, N. Khandelwal and V. 
A. Barathi, Ocul. Immunol. Inflamm., 2018, 26, 1–7. 
23 A. Baeyer, Berichte der Dtsch. Chem. Gesellschaft, 1871, 4, 555–558. 
24 A. R. Akram, S. V Chankeshwara, E. Scholefield, T. Aslam, N. 
McDonald, A. Megia-Fernandez, A. Marshall, B. Mills, N. Avlonitis, T. 
H. Craven, A. M. Smyth, D. S. Collie, C. Gray, N. Hirani, A. T. Hill, J. R. 
Govan, T. Walsh, C. Haslett, M. Bradley and K. Dhaliwal, Sci. Transl. 
Med., 2018, 10, eaal0033. 
25 C. G. Hadjipanayis, G. Widhalm and W. Stummer, Neurosurgery, 2015, 
77, 663–673. 
26 A. Mantovani, M. A. Cassatella, C. Costantini and S. Jaillon, Nat. Rev. 
Immunol., 2011, 11, 519–531. 





28 J. Pillay, I. Den Braber, N. Vrisekoop, L. M. Kwast, R. J. De Boer, J. A. 
M. Borghans, K. Tesselaar and L. Koenderman, Blood, 2010, 116, 625–
627. 
29 S. J. Galli, N. Borregaard and T. A. Wynn, Nat. Immunol., 2011, 12, 
1035–1044. 
30 E. Kolaczkowska and P. Kubes, Nat. Rev. Immunol., 2013, 13, 159–175. 
31 C. Summers, S. M. Rankin, A. M. Condliffe, N. Singh, A. M. Peters and 
E. R. Chilvers, Trends Immunol., 2010, 31, 318–324. 
32 OpenStax, Anatomy & Physiology, OpenStax CNX, 2016. 
33 B. Korkmaz, M. Horwitz, D. Jenne and F. Gauthier, Pharmacol. Rev., 
2010, 62, 726–759. 
34 C. T. N. Pham, Nat Rev Immunol, 2006, 6, 541–550. 
35 E. Kolaczkowska and P. Kubes, Nat. Rev. Immunol., 2013, 13, 159–175. 
36 V. Delgado-rizo, M. A. Martínez-guzmán, L. Iñiguez-gutierrez and M. 
Fafutis-morris, Front. Immunol., 2017, 8, 1–20. 
37 V. Papayannopoulos, Nat. Rev. Immunol., 2017, 18, 134–147. 
38 L. E. Edgington, M. Verdoes and M. Bogyo, Curr. Opin. Chem. Biol., 
2011, 15, 798–805. 
39 A. Janoff and J. Scherer, J. Exp. Med., 1968, 128, 1137–1155. 
40 B. Korkmaz, T. Moreau and F. Gauthier, Biochimie, 2008, 90, 227–242. 
41 S. J. F. Macdonald, M. D. Dowle, L. A. Harrison, G. D. E. Clarke, G. G. 
A. Inglis, M. R. Johnson, P. Shah, R. A. Smith, A. Amour, G. Fleetwood, 
D. C. Humphreys, C. R. Molloy, M. Dixon, R. E. Godward, A. J. 
Wonacott, O. M. P. Singh, S. T. Hodgson and G. W. Hardy, J. Med. 





42 W. L. Lee and G. P. Downey, Crit. Care Med., 2001, 164, 896–904. 
43 Y. Weinrauch, D. Drujan, S. D. Shapiro, J. Weiss and A. Zychlinsky, 
Nature, 2002, 417, 91–94. 
44 B. Korkmaz, M. S. Horwitz, D. E. Jenne and F. Gauthier, Pharmacol. 
Rev., 2010, 62, 726–759. 
45 U. Bank and S. Ansorge, J. Leukoc. Biol., 2001, 69, 197–206. 
46 T. J. Moraes, C.-W. Chow and G. P. Downey, Crit. Care Med., 2003, 31, 
S189–S194. 
47 A. Alase, C. W. Wasson, D. McGonagle, M. Stacey, T. Macleod, M. 
Wittmann and R. Doble, Sci. Rep., 2016, 6, 4–10. 
48 K. Tsushima, L. S. King, N. R. Aggarwal, A. De Gorordo, F. R. 
D’Alessio and K. Kubo, Intern. Med., 2009, 48, 621–630. 
49 B. Korkmaz and F. Gauthier, in Handbook of Proteolytic Enzymes, 2013, 
vol. 3, pp. 2653–2661. 
50 L. L. Warren and G. P. Downey, Am. J. Respir. Crit. Care Med., 2001, 164, 
896–904. 
51 K. C. Meyer, Semin Respir Crit Care Med, 2007, 28, 546–560. 
52 M. Drent, R. Baughman and K. Meyer, Diffus. Parenchymal Lung Dis., 
2007, 36, 58–67. 
53 B. Walker and J. Lynas, Cell. Mol. Life Sci., 2001, 58, 596–624. 
54 H. Ohbayashi, Expert Opin. Ther. Pat., 2005, 15, 759–771. 
55 W. C. Groutas, D. Dou, K. R. Alliston, W. C. Groutas, D. Dou and K. R. 
Alliston, Expert Opin. Ther. Pat., 2011, 21, 339–354. 
56 Y.-F. Tsai and T.-L. Hwang, Expert Opin. Ther. Pat., 2015, 25, 1145–1158. 





Drag, Chem. Rev., 2015, 115, 12546–12629. 
58 J. Lee and M. Bogyo, ACS Chem. Biol., 2010, 5, 233–243. 
59 C. Bremer, V. Ntziachristos and B. Weitkamp, Invest. Radiol., 2005, 40, 
321–327. 
60 D. Caglič, A. Globisch, M. Kindermann, N.-H. Lim, V. Jeske, H.-P. 
Juretschke, E. Bartnik, K. U. Weithmann, H. Nagase, B. Turk and K. U. 
Wendt, Bioorg. Med. Chem., 2011, 19, 1055–1061. 
61 H. Y. Hu, S. Gehrig, G. Reither, D. Subramanian, M. A. Mall, O. 
Plettenburg and C. Schultz, Biotechnol. J., 2014, 9, 266–281. 
62 G. Blum, G. Von Degenfeld, M. J. Merchant, H. M. Blau and M. Bogyo, 
Nat. Chem. Biol., 2007, 3, 668–677. 
63 J. B. Wu, T.-P. Lin, J. D. Gallagher, S. Kushal, L. W. K. Chung, H. E. 
Zhau, B. Z. Olenyuk and J. C. Shih, J. Am. Chem. Soc., 2015, 137, 2366–
2374. 
64 I. R. Corrêa, Curr. Opin. Chem. Biol., 2014, 20, 36–45. 
65 Nakajima, K, Powers, J.C, Ashe, B.M. & Zimmerman and M, J. Biol. 
Chem., 1979, 254, 4027-4032. 
66 L. E. Edgington, M. Verdoes and M. Bogyo, Curr. Opin. Chem. Biol., 
2011, 15, 798–805. 
67 Q. Sun, J. Li, W. N. Liu, Q. J. Dong, W. C. Yang and G. F. Yang, Anal. 
Chem., 2013, 85, 11304–11311. 
68 M. J. Castillo, K. Nakajima, M. Zimmerman and J. C. Powers, Anal. 
Biochem., 1979, 99, 53–64. 






70 M. Saikiran, D. Sato, S. S. Pandey, S. Hayase and T. Kato, Bioorg. Med. 
Chem. Lett., 2017, 27, 4024–4029. 
71 S. Gehrig, M. A. Mall and C. Schultz, Angew. Chemie - Int. Ed., 2012, 51, 
6258–6261. 
72 P. Kasperkiewicz, M. Poreba, S. J. Snipas, S. J. Lin, D. Kirchhofer, G. S. 
Salvesen and M. Drag, PLoS One, 2015, 10, e0132818. 
73 B. C. Lechtenberg, P. Kasperkiewicz, H. Robinson, M. Drag and S. J. 
Riedl, ACS Chem. Biol., 2015, 10, 945–951. 
74 M. Drag, M. D’Angelo, G. S. Salvesen, Y. Altman and P. 
Kasperkiewicz, J. Am. Chem. Soc., 2017, 139, 10115–10125. 
75 P. Kasperkiewicz, M. Poreba, S. J. Snipas, H. Parker, C. C. 
Winterbourn, G. S. Salvesen and M. Drag, Proc. Natl. Acad. Sci. U. S. A., 
2014, 111, 2518–2523. 
76 L. E. Edgington-Mitchell, N. Barlow, L. Aurelio, A. Samha, M. Szabo, B. 
Graham and N. Bunnett, Bioorg. Med. Chem. Lett., 2017, 27, 254–260. 
77 A.-C. Schulz-Fincke, M. Blaut, A. Braune and M. Gütschow, ACS Med. 
Chem. Lett., 2018, 9, 345–350. 
78 R. Huisgen, G. Szeimies and L. Möbius, Chem. Ber., 1967, 100, 2494–
2507. 
79 N. Avlonitis, M. Debunne, T. Aslam, N. McDonald, C. Haslett, K. 
Dhaliwal and M. Bradley, Org. Biomol. Chem., 2013, 11, 4414–4418. 
80 T. Craven, T. Walton, A. Akram, N. McDonald, E. Scholefield, T. 
Walsh, C. Haslett, M. Bradley and K. Dhaliwal, Lancet, 2016, 387, S31. 
81 T. H. Craven, N. Avlonitis, N. McDonald, T. Walton, E. Scholefield, A. 
R. Akram, T. S. Walsh, C. Haslett, M. Bradley and K. Dhaliwal, Sci. 





82 L. Yuan, W. Lin, K. Zheng, L. He and W. Huang, Chem. Soc. Rev., 2013, 
42, 622–661. 
83 L. M. Wysocki and L. D. Lavis, Curr. Opin. Chem. Biol., 2011, 15, 752–
759. 
84 L. D. Lavis and R. T. Raines, ACS Chem. Biol., 2007, 3, 142–155. 
85 L. D. Lavis and R. T. Raines, ACS Chem. Biol., 2014, 9, 855–866. 
86 L. Thiberville, S. Moreno-Swirc, T. Vercauteren, E. Peltier, C. Cavé and 
G. Bourg Heckly, Am. J. Respir. Crit. Care Med., 2007, 175, 22–31. 
87 A. Brunet, T. Aslam and M. Bradley, Bioorg. Med. Chem. Lett., 2014, 24, 
3186–3188. 
88 Alexafluor 647, 
https://www.thermofisher.com/order/catalog/product/A20006, 
(accessed 29 October 2018). 
89 WO Pat., 152 389, 2014, 47. 
90 M. Schottelius, A. Wurzer, K. Wissmiller, R. Beck, M. Koch, D. Gorpas, 
J. Notni, T. Buckle, M. N. Van Oosterom, K. Steiger, V. Ntziachristos, 
M. Schwaiger and F. W. B. Van Leeuwen, J. Nucl. Med., 2019, 60, 71–79. 
91 M. Miampamba, J. Liu, A. Harootunian, A. J. Gale, S. Baird, S. L. Chen, 
Q. T. Nguyen, R. Y. Tsien and J. E. González, Theranostics, 2017, 7, 
3369–3386. 
92 G. M. Robinson and R. Robinson, J. Chem. Soc. Trans., 1924, 125, 827–
840. 
93 WO Pat., 018 230, 2010, 53. 
94 WO Pat., 045 662, 2013, 49. 





and S. M. Hecht, J. Am. Chem. Soc., 2013, 135, 2883–2886. 
96 J. Burggraaf, I. M. C. Kamerling, P. B. Gordon, L. Schrier, M. L. de 
Kam, A. J. Kales, R. Bendiksen, B. Indrevoll, R. M. Bjerke, S. a Moestue, 
S. Yazdanfar, A. M. J. Langers, M. Swaerd-Nordmo, G. Torheim, M. V 
Warren, H. Morreau, P. W. Voorneveld, T. Buckle, F. W. B. van 
Leeuwen, L.-I. Ødegårdstuen, G. T. Dalsgaard, A. Healey and J. C. H. 
Hardwick, Nat. Med., 2015, 21, 955–961. 
97 S. A. Esfahani, P. Heidari, S. A. Kim, S. Ogino and U. Mahmood, 
Theranostics, 2016, 6, 2028–2038. 
98 L. I. Markova, I. A. Fedyunyayeva, Y. A. Povrozin, O. M. Semenova, S. 
U. Khabuseva, E. A. Terpetschnig and L. D. Patsenker, Dye. Pigment., 
2013, 96, 535–546. 
99 R. B. Mujumdar, L. A. Ernst, S. R. Mujumdar, C. J. Lewis and A. S. 
Waggoner, Bioconjug. Chem., 1993, 4, 105–111. 
100 US Patent Office, 8729276B, 2010, 51. 
101 S. D. Lucas, E. Costa, R. C. Guedes and R. Moreira, Med. Res. Rev., 2013, 
33, E73–E101. 
102 F. von Nussbaum and V. M.-J. Li, Bioorg. Med. Chem. Lett., 2015, 25, 
4370–4381. 
103 J. Mulchande, R. Oliveira, M. Carrasco, L. Gouveia, R. C. Guedes, J. 
Iley and R. Moreira, J Med Chem, 2010, 53, 241–253. 
104 J. Mulchande, S. I. Simões, M. M. Gaspar, C. V. Eleutério, R. Oliveira, 
M. E. M. Cruz, R. Moreira and J. Iley, J. Enzyme Inhib. Med. Chem., 2011, 
26, 169–175. 
105 J. Marto, E. Ruivo, S. D. Lucas, L. M. Gonçalves, S. Simões, L. F. 





Pharm. Biopharm., 2018, 127, 1–11. 
106 L. Glennon-alty, A. P. Hackett, E. A. Chapman and H. L. Wright, Free 
Radic. Biol. Med., 2018, 125, 25–35. 
107 E. F. P. Ruivo, L. M. Gonçalves, L. A. R. Carvalho, R. C. Guedes, S. 
Hofbauer, J. A. Brito, M. Archer, R. Moreira and S. D. Lucas, 
ChemMedChem, 2016, 11, 2037–2042. 
108 C. Haslett, L. A. Guthrie, M. M. Kopaniak, R. B. Johnston  Jr and P. M. 
Henson, Am. J. Pathol., 1985, 119, 101–110. 
109 B. G. Zeiher, A. Artigas, J.-L. Vincent, A. Dmitrienko, K. Jackson, B. T. 
Thompson and G. Bernard, Crit. Care Med., 2004, 32, 1695–1702. 
110 E. Polverino, E. Rosales-mayor, G. E. Dale, K. Dembowsky and A. 
Torres, Chest, 2017, 152, 249–262. 
111 K. Matsuzaki, Y. Hiramtsu, S. Homma, S. Sato, O. Shigeta and Y. 
Sakakibara, Ann. Thorac. Surg., 2005, 80, 611–617. 
112 K. Kawabata, M. Suzuki, M. Sugitani, K. Imaki, M. Toda and T. 
Miyamoto, Biochem. Biophys. Res. Commun., 1991, 177, 814–820. 
113 S. J. . Macdonald, M. D. Dowle, L. a Harrison, P. Shah, M. R. Johnson, 
G. G. . Inglis, G. D. . Clarke, R. a Smith, D. Humphreys, C. R. Molloy, 
A. Amour, M. Dixon, G. Murkitt, R. E. Godward, T. Padfield, T. 
Skarzynski, O. M. . Singh, K. A. Kumar, G. Fleetwood, S. T. Hodgson, 
G. W. Hardy and H. Finch, Bioorg. Med. Chem. Lett., 2001, 11, 895–898. 
114 R. E. Smith and W. R. Davis, Anal. Chem., 1984, 56, 2345–2349. 
115 S. J. F. Macdonald, G. D. E. Clarke, M. D. Dowle, L. a Harrison, S. T. 
Hodgson, G. G. a Inglis, M. R. Johnson, P. Shah, R. J. Upton and S. B. 
Walls, J. Org. Chem., 1999, 64, 5166–5175. 
 
